| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
Register now or login to post to this thread.
Craneware plc (CRW)
dreamcatcher
- 04 Sep 2012 16:49
http://www.craneware.com/Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling. Our innovative and scalable products are designed to ensure that you have the information you need to succeed in healthcare financial management.
A talented mix of employees from the healthcare industry, software engineering, business consulting, customer support and training provide the perfect blend for providing extremely powerful solutions to problems faced by hospital's financial teams.
Our consultant's years of experience in the healthcare industry are the vital source of financial, clinical and coding expertise that together with talented software developers combine to make our products so effective.
Our dedicated support team work hard at ensuring our customers always come first and pride themselves on exemplary service throughout the relationship from first install to advanced user training. Installation times are in weeks instead of months, Support responses are in minutes instead of days.
Headquartered in Scotland with offices across the US, Craneware delivers unparalleled solutions to the problems facing healthcare financial managers every day.
dreamcatcher
- 04 Sep 2012 17:11
- 2 of 99
Craneware shares up as unveils 'solid' results
http://www.proactiveinvestors.co.uk/companies/news/47664/craneware-shares-up-as-unveils-solid-results-47664.html
http://www.proactiveinvestors.co.uk/companies/news/47664/craneware-shares-up-as-unveils-solid-results-47664.html
dreamcatcher
- 05 Sep 2012 15:20
- 3 of 99
Up 7%today recovering well
dreamcatcher
- 05 Sep 2012 16:34
- 4 of 99
UP over 10% today
dreamcatcher
- 07 Sep 2012 16:40
- 5 of 99
Another good day
dreamcatcher
- 08 Sep 2012 12:45
- 6 of 99
Still rated a buy in this weeks IC.'' The shares bounced on these results although they are still downroughly 40 per cent since last october.Adjust for the cashpile and the shares now trade 14 times forecast earnings - which isn't so pricey given the impressive growth prospects''.
dreamcatcher
- 20 Sep 2012 08:36
- 7 of 99
:-))
dreamcatcher
- 25 Sep 2012 15:39
- 8 of 99
Flying up in Sept.
dreamcatcher
- 03 Nov 2012 08:49
- 9 of 99
Ex divi 9th Nov ---- divi 5.7p payed on 7th Dec
dreamcatcher
- 08 Nov 2012 08:14
- 10 of 99
Craneware chief predicts return to historic revenue growth
Wed 1:28 pm by Ian LyallIts business in outline is a very simple one. It provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits
With investors given to almost bi-polar mood swings, the smallest disappointment can lead to an almost disproportionate response.
Keith Neilson, chief executive of Craneware (LON:CRW), whose software is used in around a quarter of American hospitals, has witnessed this at close quarters.
At the moment he is enjoying the upsurge in the company’s fortunes, with stock rising (it has put on 56% since the middle of August), the outlook is improving, and one of the company’s main competitors is in retreat.
What a contrast with the early portion of 2012, which saw the stock knocked from pillar to post after a first profits warning since listing in 2007.
The slip-up was the result of a “perfect storm” of a lost contract and a slowdown in the US market as the healthcare system dealt with the introduction of electronic records.
The challenge for Neilson and his team has been convincing the market it is over the hump and Craneware is ready to return to its previous growth trajectory.
The strong rally of the share price suggests the message is finally starting to get through after some initial fears the electronic records hiatus was yet to fully run its course.
A share price of 436 pence still places the company on a forward price-to-earnings multiple of 13-14 times when it has traditionally traded in the low 20s.
Getting Craneware back to these levels will rely on management capitalising on some large potential opportunities in the space.
Its business in outline is a very simple one. It provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits.
That might sound fairly straightforward, but the US system is as complicated as it is dysfunctional.
Since IPO, the group has doubled its market share to 25 per cent, which helped it generate revenues of $41 million last financial year and profits of almost $12 million.
Over 80 per cent of its sales are recurring. The company is paid upfront each year and contracts tend to run for five years at a time, which gives it a lot of forward visibility.
Craneware is currently renewing existing customers at a rate of 109 per cent of the value of the original, which suggests it has been able to squeeze through price rises.
The hiccup this year has meant that top line growth was a comparatively pedestrian 8 per cent.
Neilson is predicting it will return to historic levels of ‘high teens, or early 20s’ per cent growth.
There is a potentially huge market opportunity in the order of US$1.5-US$2bn, he adds, that could come from growing its market share, selling more products and data to customers.
Currently, hospitals take an average of 1.6 products from a suite of nine.
There is also the opportunity to sell online to those businesses not already taking its software, Neilson suggests.
Of course the company will be going aggressively for market share as its leading competitor in the space looks to be beating a retreat from the sector.
The data that its software is able to generate will also be an increasing source of new revenues as health system and practitioners, under huge potential pressure and the weight of an ageing population, look to work smarter.
“Because of the data we are gathering the opportunities to diversify what we do organically by providing content back to hospitals and big pharma are really huge for us,” says Neilson.
“We could be looking to sell content and data plays - whether that is benchmarking, or looking at the efficacy of drugs.
“There is real ‘stick-ability’ of the software play now. But there is real longevity in the way we want to take the company.”
With around $29 million in the bank, the group is well capitalised.
It begs the question as to what Craneware might do with this cash pile – return it to shareholders, invest it or spend the money on an acquisition?
“We have been asked if we are going to return cash in future,” says Neilson.
“And the answer is possibly, yes. We continue to grow cash, we are cash generative.
“But equally we have to ensure we can take advantage of any opportunities out there in the marketplace.
“We are dealing with large enterprises signing up for five plus years.
“And they want to see we have the financial strength and prudence to do that.”
Pressed on the potential of making an acquisition, the Craneware CEO sounds a note of caution.
“If we’d been speaking a year ago when we had four or five products our priorities then would be product portfolio, market share and domain expertise,” he explains.
“That has probably reversed in the last year as we now have quite a broad suite.
“Now what we need to do is continue with domain expertise and the market share piece.
“As you know acquisitions never come along when you want them. So never say never.”
City broker Investec acknowledges that the recently published prelims told the story of a year marred by disruption.
However, analyst James Goodman also reckons the financial performance was still reasonably solid, which he says is testament to Craneware’s robust business model.
“Commentary around the underlying core market improving (month-on-month sales growth since January) and a better explanation of large, contractual opportunities have helped the shares move higher,” Goodman adds.
“But they remain cheap given their underlying quality and the market opportunity.”
Wed 1:28 pm by Ian LyallIts business in outline is a very simple one. It provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits
With investors given to almost bi-polar mood swings, the smallest disappointment can lead to an almost disproportionate response.
Keith Neilson, chief executive of Craneware (LON:CRW), whose software is used in around a quarter of American hospitals, has witnessed this at close quarters.
At the moment he is enjoying the upsurge in the company’s fortunes, with stock rising (it has put on 56% since the middle of August), the outlook is improving, and one of the company’s main competitors is in retreat.
What a contrast with the early portion of 2012, which saw the stock knocked from pillar to post after a first profits warning since listing in 2007.
The slip-up was the result of a “perfect storm” of a lost contract and a slowdown in the US market as the healthcare system dealt with the introduction of electronic records.
The challenge for Neilson and his team has been convincing the market it is over the hump and Craneware is ready to return to its previous growth trajectory.
The strong rally of the share price suggests the message is finally starting to get through after some initial fears the electronic records hiatus was yet to fully run its course.
A share price of 436 pence still places the company on a forward price-to-earnings multiple of 13-14 times when it has traditionally traded in the low 20s.
Getting Craneware back to these levels will rely on management capitalising on some large potential opportunities in the space.
Its business in outline is a very simple one. It provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits.
That might sound fairly straightforward, but the US system is as complicated as it is dysfunctional.
Since IPO, the group has doubled its market share to 25 per cent, which helped it generate revenues of $41 million last financial year and profits of almost $12 million.
Over 80 per cent of its sales are recurring. The company is paid upfront each year and contracts tend to run for five years at a time, which gives it a lot of forward visibility.
Craneware is currently renewing existing customers at a rate of 109 per cent of the value of the original, which suggests it has been able to squeeze through price rises.
The hiccup this year has meant that top line growth was a comparatively pedestrian 8 per cent.
Neilson is predicting it will return to historic levels of ‘high teens, or early 20s’ per cent growth.
There is a potentially huge market opportunity in the order of US$1.5-US$2bn, he adds, that could come from growing its market share, selling more products and data to customers.
Currently, hospitals take an average of 1.6 products from a suite of nine.
There is also the opportunity to sell online to those businesses not already taking its software, Neilson suggests.
Of course the company will be going aggressively for market share as its leading competitor in the space looks to be beating a retreat from the sector.
The data that its software is able to generate will also be an increasing source of new revenues as health system and practitioners, under huge potential pressure and the weight of an ageing population, look to work smarter.
“Because of the data we are gathering the opportunities to diversify what we do organically by providing content back to hospitals and big pharma are really huge for us,” says Neilson.
“We could be looking to sell content and data plays - whether that is benchmarking, or looking at the efficacy of drugs.
“There is real ‘stick-ability’ of the software play now. But there is real longevity in the way we want to take the company.”
With around $29 million in the bank, the group is well capitalised.
It begs the question as to what Craneware might do with this cash pile – return it to shareholders, invest it or spend the money on an acquisition?
“We have been asked if we are going to return cash in future,” says Neilson.
“And the answer is possibly, yes. We continue to grow cash, we are cash generative.
“But equally we have to ensure we can take advantage of any opportunities out there in the marketplace.
“We are dealing with large enterprises signing up for five plus years.
“And they want to see we have the financial strength and prudence to do that.”
Pressed on the potential of making an acquisition, the Craneware CEO sounds a note of caution.
“If we’d been speaking a year ago when we had four or five products our priorities then would be product portfolio, market share and domain expertise,” he explains.
“That has probably reversed in the last year as we now have quite a broad suite.
“Now what we need to do is continue with domain expertise and the market share piece.
“As you know acquisitions never come along when you want them. So never say never.”
City broker Investec acknowledges that the recently published prelims told the story of a year marred by disruption.
However, analyst James Goodman also reckons the financial performance was still reasonably solid, which he says is testament to Craneware’s robust business model.
“Commentary around the underlying core market improving (month-on-month sales growth since January) and a better explanation of large, contractual opportunities have helped the shares move higher,” Goodman adds.
“But they remain cheap given their underlying quality and the market opportunity.”
dreamcatcher
- 08 Nov 2012 08:16
- 11 of 99
RNS Number : 6294Q
Craneware plc
08 November 2012
Craneware plc
("Craneware" or the "Company")
AGM Statement
8 November 2012 - Craneware(AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, will be holding its Annual General Meeting at 10am today at the Company's headquarters in Edinburgh, Scotland. At the meeting Keith Neilson, CEO of the Company, will make the following statement:
"Fiscal and regulatory pressures on US hospitals continue to drive interest in our suite of software solutions. Sales activity continues to build, which combined with our increased market presence, strong pipeline and high levels of revenue visibility give us confidence in achieving a successful year and beyond."
Craneware plc
08 November 2012
Craneware plc
("Craneware" or the "Company")
AGM Statement
8 November 2012 - Craneware(AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, will be holding its Annual General Meeting at 10am today at the Company's headquarters in Edinburgh, Scotland. At the meeting Keith Neilson, CEO of the Company, will make the following statement:
"Fiscal and regulatory pressures on US hospitals continue to drive interest in our suite of software solutions. Sales activity continues to build, which combined with our increased market presence, strong pipeline and high levels of revenue visibility give us confidence in achieving a successful year and beyond."
dreamcatcher
- 08 Nov 2012 11:02
- 12 of 99
Craneware shares climb ahead of AGM
9:35 am by Ian LyallCraneware provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits
Software specialist Craneware’s (LON:CRW) shares spiked 7% in early deals ahead of what is likely to be an upbeat statement from the company’s chief executive at the annual meeting.
Keith Neilson will tell attendees in Edinburgh: “Fiscal and regulatory pressures on US hospitals continue to drive interest in our suite of software solutions.
“Sales activity continues to build, which combined with our increased market presence, strong pipeline and high levels of revenue visibility give us confidence in achieving a successful year and beyond.”
Craneware provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits.
That might sound fairly straightforward, but the US system is as complicated as it is dysfunctional.
Since IPO, the group has doubled its market share to 25%, which helped it generate revenues of $41 million last financial year and profits of almost $12 million.
Over 80% of its sales are recurring. The company is paid upfront each year and contracts tend to run for five years at a time, which gives it a lot of forward visibility.
Craneware is currently renewing existing customers at a rate of 109% of the value of the original, which suggests it has been able to squeeze through price rises.
However a slowdown earlier this year meant that top line growth was a comparatively pedestrian 8%.
In an interview with Proactive Investors earlier this week, Neilson predicted a return to historic growth levels of ‘high teens, or early 20s’ per cent.
The response to Neilson’s comments ahead of today’s meeting pushed the shares 30 pence higher to 456 pence.
In the last three months they have advanced 66%.
9:35 am by Ian LyallCraneware provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits
Software specialist Craneware’s (LON:CRW) shares spiked 7% in early deals ahead of what is likely to be an upbeat statement from the company’s chief executive at the annual meeting.
Keith Neilson will tell attendees in Edinburgh: “Fiscal and regulatory pressures on US hospitals continue to drive interest in our suite of software solutions.
“Sales activity continues to build, which combined with our increased market presence, strong pipeline and high levels of revenue visibility give us confidence in achieving a successful year and beyond.”
Craneware provides the software that ensures American hospitals bill for their services correctly and can deal with an increasing amount of audits.
That might sound fairly straightforward, but the US system is as complicated as it is dysfunctional.
Since IPO, the group has doubled its market share to 25%, which helped it generate revenues of $41 million last financial year and profits of almost $12 million.
Over 80% of its sales are recurring. The company is paid upfront each year and contracts tend to run for five years at a time, which gives it a lot of forward visibility.
Craneware is currently renewing existing customers at a rate of 109% of the value of the original, which suggests it has been able to squeeze through price rises.
However a slowdown earlier this year meant that top line growth was a comparatively pedestrian 8%.
In an interview with Proactive Investors earlier this week, Neilson predicted a return to historic growth levels of ‘high teens, or early 20s’ per cent.
The response to Neilson’s comments ahead of today’s meeting pushed the shares 30 pence higher to 456 pence.
In the last three months they have advanced 66%.
dreamcatcher
- 08 Nov 2012 18:07
- 13 of 99
Craneware sales activity continues to build
StockMarketWire.com
Craneware's sales activity continues to build, which combined with its increased market presence, strong pipeline and high levels of revenue visibility gives it confidence in achieving a successful year and beyond.
At 10:00am: (LON:CRW) share price was +22.5p at 448.5p
Story provided by StockMarketWire.com
StockMarketWire.com
Craneware's sales activity continues to build, which combined with its increased market presence, strong pipeline and high levels of revenue visibility gives it confidence in achieving a successful year and beyond.
At 10:00am: (LON:CRW) share price was +22.5p at 448.5p
Story provided by StockMarketWire.com
dreamcatcher
- 08 Nov 2012 18:07
- 14 of 99
Result of AGM
RNS
RNS Number : 6596Q
Craneware plc
08 November 2012
Craneware plc
("Craneware" or the "Company")
Result of AGM
8 November 2012 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces that all resolutions put to shareholders at the Company's AGM held today were duly passed.
RNS
RNS Number : 6596Q
Craneware plc
08 November 2012
Craneware plc
("Craneware" or the "Company")
Result of AGM
8 November 2012 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces that all resolutions put to shareholders at the Company's AGM held today were duly passed.
dreamcatcher
- 09 Nov 2012 07:05
- 15 of 99
Dividend Currency Election
RNS
RNS Number : 7121Q
Craneware plc
09 November 2012
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
9 November 2012 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, today gives further information regarding its final dividend announced on 4 September 2012.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who register to do so by the close of business on 9 November 2012, the dividend will be paid at an exchange rate of $1.598/£1.
RNS
RNS Number : 7121Q
Craneware plc
09 November 2012
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
9 November 2012 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, today gives further information regarding its final dividend announced on 4 September 2012.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, or who register to do so by the close of business on 9 November 2012, the dividend will be paid at an exchange rate of $1.598/£1.
dreamcatcher
- 19 Nov 2012 16:03
- 16 of 99
Craneware: Investec raises target price from 410p to 475p and downgrades from buy to hold.
dreamcatcher
- 19 Nov 2012 20:09
- 17 of 99
Craneware downgraded by Investec
Investec has downgraded its recommendation on Healthcare software company Craneware [LON:CRW] to ‘hold’ from ‘buy’ as the shares are now considered to be fairly valued after their recent strong run.
The City broker has increased its share price target by 16 per cent to 475 pence from 410 pence.
Analyst James Goodman commented: “Craneware shares have had a tremendous run, up 70% in three months.
“We continue to see Craneware as an exciting and high-quality investment proposition in an attractive structural growth market.
“However, we believe Craneware is now trading at fair value, ahead of more material evidence of a return to positive forecast momentum.
“With the recent annual general meeting statement having provided a level of further comfort we move our target price to 475 pence (from 410 pence), but our recommendation to hold (from buy).”
At 11:45 am shares in Craneware were up 0.25 pence at 476 pence.
Investec has downgraded its recommendation on Healthcare software company Craneware [LON:CRW] to ‘hold’ from ‘buy’ as the shares are now considered to be fairly valued after their recent strong run.
The City broker has increased its share price target by 16 per cent to 475 pence from 410 pence.
Analyst James Goodman commented: “Craneware shares have had a tremendous run, up 70% in three months.
“We continue to see Craneware as an exciting and high-quality investment proposition in an attractive structural growth market.
“However, we believe Craneware is now trading at fair value, ahead of more material evidence of a return to positive forecast momentum.
“With the recent annual general meeting statement having provided a level of further comfort we move our target price to 475 pence (from 410 pence), but our recommendation to hold (from buy).”
At 11:45 am shares in Craneware were up 0.25 pence at 476 pence.
dreamcatcher
- 14 Dec 2012 16:47
- 18 of 99
Sp drop of over 7% on 12,000 shares sold ?
dreamcatcher
- 21 Jan 2013 07:10
- 19 of 99
Trading Update
RNS
RNS Number : 9376V
Craneware plc
21 January 2013
Craneware plc
("Craneware" or the "Company")
Trading Update
21 January 2013 - Craneware(AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the six month period ended 31 December 2012.
Trading has been positive in the first half of the financial year and the Company expects to report revenue growth to $20.1m (H112: $18.8m) with further growth at the adjusted EBITDA level of approximately 15% in comparison to the same period in the prior year (H112: $4.65m). This performance is in line with management's expectations, delivering similar first half to second half expectation splits as those seen in the previous financial year.
Keith Neilson, CEO of Craneware,commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth. Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Program, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
Craneware will be announcing its Interim Results on 26 February 2013
RNS
RNS Number : 9376V
Craneware plc
21 January 2013
Craneware plc
("Craneware" or the "Company")
Trading Update
21 January 2013 - Craneware(AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the six month period ended 31 December 2012.
Trading has been positive in the first half of the financial year and the Company expects to report revenue growth to $20.1m (H112: $18.8m) with further growth at the adjusted EBITDA level of approximately 15% in comparison to the same period in the prior year (H112: $4.65m). This performance is in line with management's expectations, delivering similar first half to second half expectation splits as those seen in the previous financial year.
Keith Neilson, CEO of Craneware,commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth. Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Program, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
Craneware will be announcing its Interim Results on 26 February 2013
dreamcatcher
- 21 Jan 2013 08:24
- 20 of 99
Revenue growth continues at Craneware
Mon 21 Jan 2013
CRW - Craneware
Latest Prices
Name Price %
Craneware 387.50p 0.00%
FTSE AIM 100 3,303 +0.05%
FTSE AIM All-Share 739 +0.07%
Software & Computer Services 982 +0.06%
LONDON (SHARECAST) - US healthcare software developer Craneware said first half trading has been positive as increased levels of sales start to contribute to revenue growth.
The group, which provides monitoring and automated revenue systems, said it expects to report revenue growth to $20.1m, up from $18.8m in the same half in 2012 with further growth at the adjusted EBITDA level of around 15% from the same period last year.
Craneware said this performance is in line with management's expectations, "delivering similar first half to second half expectation splits as those seen in the previous financial year."
CEO Keith Neilson commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth."
"Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Programme, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
Mon 21 Jan 2013
CRW - Craneware
Latest Prices
Name Price %
Craneware 387.50p 0.00%
FTSE AIM 100 3,303 +0.05%
FTSE AIM All-Share 739 +0.07%
Software & Computer Services 982 +0.06%
LONDON (SHARECAST) - US healthcare software developer Craneware said first half trading has been positive as increased levels of sales start to contribute to revenue growth.
The group, which provides monitoring and automated revenue systems, said it expects to report revenue growth to $20.1m, up from $18.8m in the same half in 2012 with further growth at the adjusted EBITDA level of around 15% from the same period last year.
Craneware said this performance is in line with management's expectations, "delivering similar first half to second half expectation splits as those seen in the previous financial year."
CEO Keith Neilson commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth."
"Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Programme, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
dreamcatcher
- 21 Jan 2013 09:38
- 21 of 99
Craneware: Investec moves target price from 475p to 410p and stays with its hold rating.
dreamcatcher
- 26 Feb 2013 07:09
- 22 of 99
Half Yearly Report
RNS
RNS Number : 6339Y
Craneware plc
26 February 2013
Craneware plc
("Craneware", "the Group" or the "Company")
Interim Results
26 February 2013 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2012.
Financial Highlights (US dollars)
· Revenue increased 7% to $20.1m (H112: $18.8m)
· Adjusted EBITDA1 increased 15% to $5.4m (H112: $4.7m )
· Profit before tax $4.5m (H112: $3.8m)
· Adjusted basic EPS increased 18% to 13.2 cents per share (H112: 11.2 cents)
· Cash at period end $28.6m (H112: $23.6m) from $28.8m at 30 June 2012
· Proposed interim dividend of 5.2p (H112: 4.8p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments, released deferred consideration and transaction related costs
Operational Highlights
· 2012 Best in KLAS Awards: Software & Services
· Particularly strong performance from InSight Audit
· Supportive market environment
· Good revenue visibility over the remainder of the year
Keith Neilson, CEO of Craneware commented:
"This has been a positive trading period for Craneware. Sales activity is ahead of the same period last year and is now starting to translate into revenue growth. The relevance of our product set continues to strengthen in the evolving healthcare landscape with the developments within the US healthcare market supportive of the Group's long-term strategy and growth.""
dreamcatcher
- 26 Jun 2013 15:07
- 23 of 99
Trading Update
RNS
RNS Number : 8557H
Craneware plc
26 June 2013
Craneware plc
("Craneware", the "Group" or the "Company")
Trading Update
26 June 2013 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the year ending 30 June 2013.
The Group continues to see increased levels of sales activity and conversion of its growing sales pipeline into revenue in our underlying small and medium sized hospital business. Progress also continues to be made with a significant number of large sales opportunities. It has not, however, been possible to sign one of these large deals in this period due mainly to corporate activity within this customer base. Management expects that the likelihood of one of these deals closing before the end of the financial year is now low. In the past, at least one of these large sales deals has contributed to revenue growth in any individual year, as was the case in 2012.
As such, without the contribution from new large deals and with the final month of the financial year still to complete, the Board expects to report revenue for the year in a range of $41 million to $42 million and adjusted EBITDA in a range of $11.9 million to $12.6 million, both in line or marginally ahead of the prior year but below current market expectations.
Our historical success in large hospital networks and other 'routes to market' confirms the demand for our product set in this significant sector of the market. However, these sales are more complex and involve a much longer sales cycle which is inevitably harder to predict, particularly when further complicated by current high levels of corporate activity in this segment. The investment we made during the year in our sales force has produced the expected positive results in our underlying small and medium sized business. Looking forward, the Company will be dedicating more resources on large hospital networks and other routes to market to specifically focus on delivering revenue growth from these sectors on a more predictable basis.
Keith Neilson, CEO of Craneware,commented, "The success we have seen in our investment in sales is not fully reflected in these results due to the large deals we have in the pipeline not closing during this year. Although we believe we have been hampered in our efforts to close these deals by corporate activity within our customer base, this trend of consolidation will not ease. We will therefore continue to build our focused team dedicated to servicing these organisations which we believe will provide us with better predictability and ultimately a greater success in closing these deals in the future. Fiscal and regulatory pressures on all US hospitals continues to drive interest in our unique suite of solutions and we are confident in the ongoing strength and relevance of our position within the US healthcare market."
26 Jun Investec 365.00 Buy
26 Jun Numis 390.00 Hold
26 Jun Espirito... 375.00 Neutral
dreamcatcher
- 09 Aug 2013 16:08
- 24 of 99
Lifted from a low of 330 odd. 9% rise today
dreamcatcher
- 10 Sep 2013 07:27
- 25 of 99
Final Results
RNS
RNS Number : 5739N
Craneware plc
10 September 2013
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
10 September 2013 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its results for the year ended 30 June 2013.
Financial Highlights (US dollars)
· Revenue increased 1% to $41.5m (2012: $41.1m)
· Adjusted EBITDA1 increased 4% to $12.4m (2012: $11.9m)
· Adjusted profit before taxation increased 4% to $11.2m (2012: $10.8m)
· Profit before tax decreased 5% to $10.6m (2012: $11.2m)
· Basic adjusted EPS increased 4% to 32.9 cents (2012: 31.6 cents), basic EPS decreased 7% to 30.7 cents (2012: 33.0 cents)
· Cash at year end $30.3m (2012: $28.8m) after returning $4.7m to shareholders by way of dividends
· Proposed final dividend of 6.3p (9.6 cents) per share giving total dividend for the year of 11.5p (17.4 cents) (2012: 10.5p /15.9 cents per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments, released deferred consideration and transaction related costs
Operational Highlights
· Underlying growth in sales to individual hospitals and small hospital groups
· Exited the year with significantly higher sales run rate than at the start
· Renewal rates over 100% of dollar value
· Products achieved top rankings within their divisions of the KLAS industry awards
· Hospitals continue to face growing financial and administrative pressure including increased audit activity and significant backlogs in the appeal process
· Key appointments increase bandwidth of senior management team
Keith Neilson, CEO of Craneware commented: "Overall Group revenue reported in the year was marginally ahead of that of last year, masking the steady growth through the year in sales to individual hospitals, which was very encouraging and a reflection of the more stable trading environment. The strengthening of sales activity has continued and trading in the first few months of the new financial year has been healthy. With a product suite that addresses many of the fundamental financial issues besetting healthcare providers in the US, an invigorated sales team and a more stable trading environment, we are confident Craneware has the platform to deliver increased shareholder value in the years ahead."
dreamcatcher
- 07 Mar 2014 14:10
- 26 of 99
Northland Capital Partners view -
Tuesday also sees interims from Craneware (LON:CRW). The most recent IMS suggested revenue and EBITDA growth of 5%. Craneware adopts a conservative subscription revenue recognition policy and enjoys very high renewal rates but a sale to a large hospital group or other routes to market, has been absent recently. Steps have been taken to address this and we expect a status update.
Tuesday also sees interims from Craneware (LON:CRW). The most recent IMS suggested revenue and EBITDA growth of 5%. Craneware adopts a conservative subscription revenue recognition policy and enjoys very high renewal rates but a sale to a large hospital group or other routes to market, has been absent recently. Steps have been taken to address this and we expect a status update.
dreamcatcher
- 11 Mar 2014 17:43
- 27 of 99
Half Yearly Report
Financial Highlights (US dollars)
· Revenue increased 5% to $21.1m (H1 2013: $20.1m)
· Adjusted EBITDA1 increased 6% to $5.7m (H1 2013: $5.4m)
· Profit before tax increased 7% to $4.8m (H1 2013: $4.5m)
· Adjusted basic EPS increased 8% to 14.3 cents per share (H1 2013: 13.2 cents per share)
· Cash at period end $30.6m (H1 2013: $28.6m and $30.3m at 30 June 2013)
· Proposed interim dividend of 5.7p per share (H1 2013: 5.2p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments, released deferred consideration and transaction related costs
Operational Highlights
· Good sales performance driven by incremental increases in the number of deals, in the size of hospital groups, the overall deal size and the number of longer-term contracts
· 2013 Best in KLAS Awards: Chargemaster Toolkit and Bill Analyzer
· Good growth in InSight Audit supporting the 'Gateway Products' strategy
· Supportive market environment - The Affordable Care Act, new billing models, healthcare consumerisation, RAC and third party payor audits, market consolidation and affiliations
· Strong revenue visibility over the remainder of the year and beyond
http://www.moneyam.com/action/news/showArticle?id=4770172
Financial Highlights (US dollars)
· Revenue increased 5% to $21.1m (H1 2013: $20.1m)
· Adjusted EBITDA1 increased 6% to $5.7m (H1 2013: $5.4m)
· Profit before tax increased 7% to $4.8m (H1 2013: $4.5m)
· Adjusted basic EPS increased 8% to 14.3 cents per share (H1 2013: 13.2 cents per share)
· Cash at period end $30.6m (H1 2013: $28.6m and $30.3m at 30 June 2013)
· Proposed interim dividend of 5.7p per share (H1 2013: 5.2p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments, released deferred consideration and transaction related costs
Operational Highlights
· Good sales performance driven by incremental increases in the number of deals, in the size of hospital groups, the overall deal size and the number of longer-term contracts
· 2013 Best in KLAS Awards: Chargemaster Toolkit and Bill Analyzer
· Good growth in InSight Audit supporting the 'Gateway Products' strategy
· Supportive market environment - The Affordable Care Act, new billing models, healthcare consumerisation, RAC and third party payor audits, market consolidation and affiliations
· Strong revenue visibility over the remainder of the year and beyond
http://www.moneyam.com/action/news/showArticle?id=4770172
dreamcatcher
- 11 Mar 2014 17:47
- 28 of 99
Obamacare boosts Craneware
By Jamie Nimmo
March 11 2014, 4:30pm
Craneware's software systems allow hospitals to write bills and claims to ensure they receive the cash they are entitled to
Craneware (LON:CRW) enjoyed a rise in half-year profits as the hospital software billing specialist benefited from the complexity of the Affordable Care Act, otherwise known as ‘Obamacare’ in the US.
Revenues in the six months ended December rose 5% to $21.1mln, while pre-tax profits picked up 7% to $4.8mln.
The company's software systems allow hospitals to write bills and claims to ensure they receive the cash they are entitled to.
Its client base consists of around a quarter of all hospitals in the states.
“The key to us is all the underlying pieces in that the complexity of the whole system in the US isn’t going to get easier,” explains chief executive Keith Neilson.
“You’ve got this mix of procedures, technology, potentially new expensive drugs coming through, gene therapies. And the people who are paying for that, whether that be the patient or the government, want to get insight into exactly what they are doing.
“That’s where we come in. We can give that insight and make sure our customers, the hospitals, claim for the reimbursement for providing these services and treatments correctly following the rules and regulations.”
Speaking to Proactive Investors, Neilson says the aim is to get back into double digit growth “as quickly as possible”.
“We expect to be able to achieve that over the next couple of years.”
Geographic expansion meanwhile remains an option, but growing the business further in the US comes first.
“We’ve just scratched the surface of the $31bn spend on software and IT in a very small part of our space,” Neilson says.
“We want to be able to rapidly accelerate our business so we’re getting a bigger share of that and be able to serve far more customers in a far deeper way with a far broader range of products than we currently do – and that’s where our growth will come from.
“If we bring in geographic expansion it will be because of a specific opportunity that’s there.”
The company ended the year with $30.6mln in cash and is open to acquisitions.
The shares were flat at 585p on Tuesday, valuing the company at £158mln.
By Jamie Nimmo
March 11 2014, 4:30pm
Craneware's software systems allow hospitals to write bills and claims to ensure they receive the cash they are entitled to
Craneware (LON:CRW) enjoyed a rise in half-year profits as the hospital software billing specialist benefited from the complexity of the Affordable Care Act, otherwise known as ‘Obamacare’ in the US.
Revenues in the six months ended December rose 5% to $21.1mln, while pre-tax profits picked up 7% to $4.8mln.
The company's software systems allow hospitals to write bills and claims to ensure they receive the cash they are entitled to.
Its client base consists of around a quarter of all hospitals in the states.
“The key to us is all the underlying pieces in that the complexity of the whole system in the US isn’t going to get easier,” explains chief executive Keith Neilson.
“You’ve got this mix of procedures, technology, potentially new expensive drugs coming through, gene therapies. And the people who are paying for that, whether that be the patient or the government, want to get insight into exactly what they are doing.
“That’s where we come in. We can give that insight and make sure our customers, the hospitals, claim for the reimbursement for providing these services and treatments correctly following the rules and regulations.”
Speaking to Proactive Investors, Neilson says the aim is to get back into double digit growth “as quickly as possible”.
“We expect to be able to achieve that over the next couple of years.”
Geographic expansion meanwhile remains an option, but growing the business further in the US comes first.
“We’ve just scratched the surface of the $31bn spend on software and IT in a very small part of our space,” Neilson says.
“We want to be able to rapidly accelerate our business so we’re getting a bigger share of that and be able to serve far more customers in a far deeper way with a far broader range of products than we currently do – and that’s where our growth will come from.
“If we bring in geographic expansion it will be because of a specific opportunity that’s there.”
The company ended the year with $30.6mln in cash and is open to acquisitions.
The shares were flat at 585p on Tuesday, valuing the company at £158mln.
dreamcatcher
- 02 Apr 2014 07:10
- 29 of 99
Significant Contract Wins
RNS
RNS Number : 8274D
Craneware plc
02 April 2014
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Wins
2 April 2014 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, is pleased to announce the signing of two new significant multi-year contracts with large multi-system hospital groups in the eastern US. The first contract is expected to deliver $3.8m revenue to the Group during the five year term while the second will deliver in excess of $3.1m over its seven year term. The Company's revenue recognition policy means that whilst initial implementation is scheduled in the current financial year, the full impact of the revenue will be seen from FY15 onwards.
The first hospital system comprises over 1200 staffed beds and incorporates multiple specialty care facilities and programs. The contract is for the implementation of Chargemaster Toolkit®, Online Reference Toolkit®, Physician Revenue Toolkit®, Pharmacy ChargeLink®, Supplies ChargeLink®, and related professional services. Chargemaster Toolkit will be utilised by the organisation across its member hospitals to reduce billing errors, ensure the timely and accurate submission of claims and manage compliance risk. Pharmacy ChargeLink and Supplies ChargeLink will allow the organisation to establish a critical connection between pharmaceutical and supply purchases and billing - ultimately, improving charge capture, coding and financial performance.
The second hospital system, which has over 3000 staffed beds, has contracted for Craneware's gateway Pharmacy ChargeLink product and related services.
This follows the signing of a nine year multi-product contract with a medium sized hospital group in the first half of the year, which following the addition of further products during the quarter just finished, now has a cumulative contract value in excess of $3.5m.
Keith Neilson, CEO of Craneware plc commented, "We are delighted to have secured these three significant contracts in recent weeks, all of which contain strategic product sets over multiple years. These competitive wins demonstrate the relevance of the Craneware product suite to all sectors of the US healthcare provider market, building on the increase in sales we have witnessed in the first half of the financial year and underline our leading position within the revenue integrity marketplace."
dreamcatcher
- 02 Apr 2014 16:15
- 30 of 99
2 Apr Investec 645.00 Buy
2 Apr N+1 Singer 590.00 Hold
2 Apr N+1 Singer 590.00 Hold
dreamcatcher
- 15 Jul 2014 07:10
- 31 of 99
Trading Update
RNS
RNS Number : 2877M
Craneware plc
15 July 2014
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Notice of Results
15 July 2014 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2014.
The Board is pleased to confirm the increased sales activity reported earlier in the year has delivered a record sales performance for the Group with the total value of contracts signed in the year increasing to over $70m (FY13: $38.5m), an increase in excess of 80% on the prior year.
In accordance with the Group's revenue recognition policy, which is focussed on long term sustainable growth and mitigates against year on year fluctuations in the total value of contracts signed, the vast majority of the revenue from these sales has not been recognised in the year to 30 June 2014, and will instead benefit future years. Accordingly the Group expects to report revenues in a range of $42.2m to $43m (FY13: $41.5m) and deliver an adjusted EBITDA in a range of $12.8m to $13.2m (FY13: $12.4m).
The market for revenue integrity solutions continues to develop with larger and more complex hospital systems becoming an increasing part of both current year sales and the pipeline of sales opportunities. We continue to invest in our sales organisation to ensure we are optimally positioned to take advantage of this growing market opportunity. Management believes as the fiscal and regulatory pressures on US hospitals continue to grow, the strength and relevance of our unique suite of solutions will increase in this market environment, giving us confidence in continued future growth.
Keith Neilson, CEO of Craneware plc commented, "We are delighted to announce a record sales year for the Group, with a year on year increase of over 80% in the total value of contracts signed in the year, demonstrating the ongoing strength of our market position. The current sales success gives Craneware certainty over contracted revenue and associated profits upon which to build future growth."
The Company will announce its Full Year Results on 16th September 2014.
dreamcatcher
- 16 Sep 2014 07:22
- 32 of 99
Final Results
RNS
RNS Number : 7393R
Craneware plc
16 September 2014
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
16 September 2014 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its results for the year ended 30 June 2014.
Financial Highlights (US dollars)
· Record total contract value signed in the year of $71.0m (FY13: $38.5m)
· Revenue increased to $42.6m (2013: $41.5m)
· Adjusted EBITDA1 increased to $13.1m (2013: $12.4m)
· Adjusted profit before taxation increased to $11.9m (2013: $11.2m)
· Profit before tax increased to $11.3m (2013: $10.6m)
· Basic adjusted EPS increased to 34.0 cents (2013: 32.9 cents), basic EPS increased to 31.9 cents (2013: 30.7 cents)
· Positive operational cash flow of $10.2m (2013: $9.9m)
· Cash at year end $32.6m (2013: $30.3m) after payment of $5.4m dividend to shareholders
· Proposed final dividend of 6.8p (11.63 cents) per share giving total dividend for the year of 12.5p (21.37 cents) (2013: 11.5p / 17.4 cents per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments.
Operational Highlights
· Leading indicators of customer confidence in the US healthcare market:
o Sales to all strata of hospitals
o Return of 7 and 9 year contracts
o Dollar renewal rates continue to be strong, within historic range
o Longer average renewal contract lengths
o Strong sales momentum and pipeline continues into FY15
· Supportive market environment for Craneware products due to continued regulatory and fiscal pressures on US healthcare providers
· Continued investment in product suite:
o Major enhancement releases to gateway products
o Furthering enterprise capabilities across product families
o Post year end launch of Reference Plus; and
o Acquisition of Kestros Limited
Keith Neilson, CEO of Craneware plc commented, "We have been pleased with the Group's performance in the year. We have seen signs of growing customer confidence and believe Craneware is increasingly well positioned to address a growing market opportunity in what is the largest software vertical in the world; the US healthcare market.
Craneware remains at the forefront of providing solutions to US healthcare providers to help them achieve revenue integrity through the management of their cost base whilst ensuring receipt of all legitimate reimbursement. We believe true revenue integrity is required if healthcare providers are to continue to support improved patient care and clinical outcomes.
Investments in the business mean we have the people and the expertise in place to take us through the next stage of growth, building on our record sales performance. We have had a strong start to the current year, carrying on the momentum from the previous year and are confident we have the platform to deliver ongoing increased stakeholder value."
dreamcatcher
- 16 Sep 2014 17:32
- 33 of 99
16 Sep Investec 645.00 Buy
16 Sep N+1 Singer 590.00 Buy
16 Sep N+1 Singer 590.00 Buy
dreamcatcher
- 14 Jan 2015 18:48
- 34 of 99
Trading Update
RNS
RNS Number : 0741C
Craneware plc
14 January 2015
14 January 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
14 January 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2014.
The Group is pleased to announce it has seen a further 10% increase in total value of contracts signed in the six month period ended 31 December 2014 compared to the same period last year. In accordance with the Company's revenue recognition policy the majority of revenue and margin resulting from these sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
The Group expects to report an increase of at least 10% in adjusted EBITDA for the six months ended 31 December 2014 compared with the same period last year and a modest increase in recognised revenue, in line with management's expectations. With increased revenue recognition in the second half of the year to 30 June 2015 arising from contracted sales made in prior periods, together with continuing positive sales momentum, the Board is confident in meeting market expectations for the full year.
Keith Neilson, CEO of Craneware plc commented, "The continuation of a strong sales performance, supporting ongoing growth, that increases in future periods, gives management confidence in its ability to deliver increasing stakeholder value through this year and in the future."
RNS
RNS Number : 0741C
Craneware plc
14 January 2015
14 January 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
14 January 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2014.
The Group is pleased to announce it has seen a further 10% increase in total value of contracts signed in the six month period ended 31 December 2014 compared to the same period last year. In accordance with the Company's revenue recognition policy the majority of revenue and margin resulting from these sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
The Group expects to report an increase of at least 10% in adjusted EBITDA for the six months ended 31 December 2014 compared with the same period last year and a modest increase in recognised revenue, in line with management's expectations. With increased revenue recognition in the second half of the year to 30 June 2015 arising from contracted sales made in prior periods, together with continuing positive sales momentum, the Board is confident in meeting market expectations for the full year.
Keith Neilson, CEO of Craneware plc commented, "The continuation of a strong sales performance, supporting ongoing growth, that increases in future periods, gives management confidence in its ability to deliver increasing stakeholder value through this year and in the future."
dreamcatcher
- 14 Jan 2015 18:49
- 35 of 99
14 Jan Investec 645.00 Buy
dreamcatcher
- 19 Feb 2015 15:14
- 36 of 99
19 Feb Panmure Gordon 587.00 Buy
dreamcatcher
- 10 Mar 2015 16:58
- 37 of 99
Interim Results
Financial Highlights (US dollars)
· Total contract value signed in the period increased 13%
· Revenue increased 2% to $21.6m (H1 2014: $21.1m)
· Adjusted EBITDA1 increased 10% to $6.3m (H1 2014: $5.7m)
· Profit before tax increased 10% to $5.3m (H1 2014: $4.8m)
· Adjusted basic EPS increased 15% to 16.5 cents per share (H1 2014: 14.3cents per share)
· Cash at period end $36.4m (H1 2014: $30.6m)
· Proposed interim dividend of 6.3p per share (H1 2014: 5.7p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments that include acquisition and share transaction related costs.
Operational Highlights
· Continued sales momentum in H1
· Strong performance in "2014 Best in KLAS Awards"
· First sale by Craneware Health, previously Kestros Health
· Continued product development and enhancement
Financial Highlights (US dollars)
· Total contract value signed in the period increased 13%
· Revenue increased 2% to $21.6m (H1 2014: $21.1m)
· Adjusted EBITDA1 increased 10% to $6.3m (H1 2014: $5.7m)
· Profit before tax increased 10% to $5.3m (H1 2014: $4.8m)
· Adjusted basic EPS increased 15% to 16.5 cents per share (H1 2014: 14.3cents per share)
· Cash at period end $36.4m (H1 2014: $30.6m)
· Proposed interim dividend of 6.3p per share (H1 2014: 5.7p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments that include acquisition and share transaction related costs.
Operational Highlights
· Continued sales momentum in H1
· Strong performance in "2014 Best in KLAS Awards"
· First sale by Craneware Health, previously Kestros Health
· Continued product development and enhancement
dreamcatcher
- 10 Mar 2015 16:58
- 38 of 99
Strategic Partnership with Aridhia Informatics
RNS
RNS Number : 9962G
Craneware plc
10 March 2015
10 March 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Strategic Partnership with Aridhia Informatics
10 March 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, is pleased to announce that it has entered into a strategic partnership with Aridhia Informatics ("Aridhia"), the Edinburgh-based health informatics company.
This partnership will enable Craneware to offer Aridhia's core services which includes their collaborative analytics platform, data science service and app development capability to Craneware's extensive client base on an exclusive basis. With solutions that focus on patient outcomes, this partnership supports Craneware's US healthcare offering and extends Aridhia's healthcare client base outside the UK, Australia and Kuwait.
During the last 15 years, one quarter of all registered US hospitals have chosen Craneware's medical billing software solutions to assist them on their journey to improved financial performance and revenue integrity. This partnership with Aridhia will support these hospitals' growing requirement for informatics solutions at a time when a growing number of medical insurers are moving away from fee-for-service towards performance-based reimbursement.
Keith Neilson, CEO of Craneware plc commented, "We are pleased to bring the analytics agility platform to our client base, offering Aridhia's expertise in utilising clients' data to improve patient outcomes."
David Sibbald, CEO of Aridhia, said: "US healthcare providers have traditionally focused on financial outcomes and cutting costs but they are increasingly adopting a patient centric approach which will, in turn, have a positive effect on their bottom line. Craneware works with some of the biggest healthcare providers in the US so we're very pleased to be partnering with them and using our integrated healthcare informatics solutions to deliver better operational results for the Craneware customer, hospitals and therefore, better health outcomes for their patients."
For further information, please contact:
Craneware plc
Peel Hunt
Newgate
+44 (0)131 550 3100
+44 (0)20 7418 8900
+44 (0)20 7653 9850
Keith Neilson, CEO
Dan Webster
Tim Thompson
Craig Preston, CFO
Richard Kauffer
Ed Treadwell
About Craneware
Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Arizona, Massachusetts and Tennessee employing over 200 staff. Craneware is the leader in automated revenue integrity solutions that improve financial performance for healthcare organisations. Craneware's market-driven, SaaS solutions help hospitals and other healthcare providers more effectively price, charge, code and retain earned revenue for patient care services and supplies. This optimises reimbursement, increases operational efficiency and minimises compliance risk. By partnering with Craneware, clients achieve the visibility required to identify, address and prevent revenue leakage. To learn more, visit craneware.com.
About Aridhia Informatics
Aridhia is a world-leading health informatics company developing technology and capability that supports the management of chronic diseases, personalised medicine and biomedical research through the use of biomedical informatics and analytics. Operating internationally on chronic disease management projects in Kuwait, Australia, England and Scotland, Aridhia works closely with governments, health organisations, research collaborations and academic institutions.
Aridhia was co-founded in 2007 by Dr David Sibbald a software entrepreneur, philanthropist and Vice-President of UK UNICEF, the United Nations children's fund; and Professor Andrew Morris who is Chief Scientist for Health in Scotland and recently took up the position as Professor of Medicine, Director of the Institute of Population Heath Sciences and Informatics and Vice-Principal of the University for Data Science at the University of Edinburgh.
Based in Edinburgh and Glasgow, Aridhia are made up of a multi-disciplinary team of 55, data scientists, clinicians, computer scientists, software developers and healthcare experts.
ENDS
RNS
RNS Number : 9962G
Craneware plc
10 March 2015
10 March 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Strategic Partnership with Aridhia Informatics
10 March 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, is pleased to announce that it has entered into a strategic partnership with Aridhia Informatics ("Aridhia"), the Edinburgh-based health informatics company.
This partnership will enable Craneware to offer Aridhia's core services which includes their collaborative analytics platform, data science service and app development capability to Craneware's extensive client base on an exclusive basis. With solutions that focus on patient outcomes, this partnership supports Craneware's US healthcare offering and extends Aridhia's healthcare client base outside the UK, Australia and Kuwait.
During the last 15 years, one quarter of all registered US hospitals have chosen Craneware's medical billing software solutions to assist them on their journey to improved financial performance and revenue integrity. This partnership with Aridhia will support these hospitals' growing requirement for informatics solutions at a time when a growing number of medical insurers are moving away from fee-for-service towards performance-based reimbursement.
Keith Neilson, CEO of Craneware plc commented, "We are pleased to bring the analytics agility platform to our client base, offering Aridhia's expertise in utilising clients' data to improve patient outcomes."
David Sibbald, CEO of Aridhia, said: "US healthcare providers have traditionally focused on financial outcomes and cutting costs but they are increasingly adopting a patient centric approach which will, in turn, have a positive effect on their bottom line. Craneware works with some of the biggest healthcare providers in the US so we're very pleased to be partnering with them and using our integrated healthcare informatics solutions to deliver better operational results for the Craneware customer, hospitals and therefore, better health outcomes for their patients."
For further information, please contact:
Craneware plc
Peel Hunt
Newgate
+44 (0)131 550 3100
+44 (0)20 7418 8900
+44 (0)20 7653 9850
Keith Neilson, CEO
Dan Webster
Tim Thompson
Craig Preston, CFO
Richard Kauffer
Ed Treadwell
About Craneware
Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Arizona, Massachusetts and Tennessee employing over 200 staff. Craneware is the leader in automated revenue integrity solutions that improve financial performance for healthcare organisations. Craneware's market-driven, SaaS solutions help hospitals and other healthcare providers more effectively price, charge, code and retain earned revenue for patient care services and supplies. This optimises reimbursement, increases operational efficiency and minimises compliance risk. By partnering with Craneware, clients achieve the visibility required to identify, address and prevent revenue leakage. To learn more, visit craneware.com.
About Aridhia Informatics
Aridhia is a world-leading health informatics company developing technology and capability that supports the management of chronic diseases, personalised medicine and biomedical research through the use of biomedical informatics and analytics. Operating internationally on chronic disease management projects in Kuwait, Australia, England and Scotland, Aridhia works closely with governments, health organisations, research collaborations and academic institutions.
Aridhia was co-founded in 2007 by Dr David Sibbald a software entrepreneur, philanthropist and Vice-President of UK UNICEF, the United Nations children's fund; and Professor Andrew Morris who is Chief Scientist for Health in Scotland and recently took up the position as Professor of Medicine, Director of the Institute of Population Heath Sciences and Informatics and Vice-Principal of the University for Data Science at the University of Edinburgh.
Based in Edinburgh and Glasgow, Aridhia are made up of a multi-disciplinary team of 55, data scientists, clinicians, computer scientists, software developers and healthcare experts.
ENDS
dreamcatcher
- 10 Mar 2015 16:59
- 39 of 99
10 Mar Investec 645.00 Buy
10 Mar N+1 Singer 590.00 Buy
10 Mar Panmure Gordon 609.00 Buy
10 Mar N+1 Singer 590.00 Buy
10 Mar Panmure Gordon 609.00 Buy
dreamcatcher
- 22 Mar 2015 20:29
- 40 of 99
IC- Craneware rises on US thermal.
Spiralling US health care costs and new regulations are forcing hospitals to retrench and improve value for money. Growing numbers are using Cranware's billing and payments software to accurately price and charge for treatments and supplies, helping them maximise revenue and minimise costs and billing errors. Prospects are fairly well priced in.
Spiralling US health care costs and new regulations are forcing hospitals to retrench and improve value for money. Growing numbers are using Cranware's billing and payments software to accurately price and charge for treatments and supplies, helping them maximise revenue and minimise costs and billing errors. Prospects are fairly well priced in.
dreamcatcher
- 25 Mar 2015 16:18
- 41 of 99
25 Mar SP Angel 620.00 Buy
26 Mar 2015 Craneware PLC (6.3 P) ex dividend
26 Mar 2015 Craneware PLC (6.3 P) ex dividend
dreamcatcher
- 12 May 2015 21:26
- 42 of 99
Craneware PLC (CRW.GB:ISD) set a new 52-week high during today's trading session when it reached 665.00. Over this period, the share price is up 22.02%.
dreamcatcher
- 16 Jul 2015 18:11
- 43 of 99
Trading Update and Notice of Results
RNS
RNS Number : 1810T
Craneware plc
16 July 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Notice of Results
16 July 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2015.
The Board is pleased to confirm total value of contracts signed for the year of $72.5m, building on the previous year's record sales performance.
As the Group's revenue recognition policy retains focus on long term sustainable growth and mitigates against year on year fluctuations in the total value of contracts signed, the vast majority of the revenue from these sales has not been recognised in the year to 30 June 2015, and will instead benefit future years. Accordingly the Group expects to report revenues in a range of $44.5m to $45m (FY14: $42.6m) and deliver an adjusted EBITDA in a range of $14.0m to $14.5m (FY14: $13.1m).
Other key performance indicators for the Group continue to trend well including renewals in the year above 100% (by $ value) with strong cash generation resulting in cash reserves in excess of $40m at 30 June 2015 (2014 $32.6m).
Keith Neilson, CEO of Craneware plc commented, "We are delighted with the continued level of strong sales throughout the period that underpin the Group's financial and operational performance. We believe this continues to demonstrate our solutions' importance in supporting US hospitals as they transition towards value based healthcare. Having now defined the "Value Cycle" for US Healthcare providers, Craneware's leading position in providing solutions to discover, convert and optimise value for them along with the Group's ongoing financial performance, gives management confidence in its ability to deliver continued and increasing stakeholder value."
The Company will announce its Full Year Results on 8th September 2015.
RNS
RNS Number : 1810T
Craneware plc
16 July 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Notice of Results
16 July 2015 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2015.
The Board is pleased to confirm total value of contracts signed for the year of $72.5m, building on the previous year's record sales performance.
As the Group's revenue recognition policy retains focus on long term sustainable growth and mitigates against year on year fluctuations in the total value of contracts signed, the vast majority of the revenue from these sales has not been recognised in the year to 30 June 2015, and will instead benefit future years. Accordingly the Group expects to report revenues in a range of $44.5m to $45m (FY14: $42.6m) and deliver an adjusted EBITDA in a range of $14.0m to $14.5m (FY14: $13.1m).
Other key performance indicators for the Group continue to trend well including renewals in the year above 100% (by $ value) with strong cash generation resulting in cash reserves in excess of $40m at 30 June 2015 (2014 $32.6m).
Keith Neilson, CEO of Craneware plc commented, "We are delighted with the continued level of strong sales throughout the period that underpin the Group's financial and operational performance. We believe this continues to demonstrate our solutions' importance in supporting US hospitals as they transition towards value based healthcare. Having now defined the "Value Cycle" for US Healthcare providers, Craneware's leading position in providing solutions to discover, convert and optimise value for them along with the Group's ongoing financial performance, gives management confidence in its ability to deliver continued and increasing stakeholder value."
The Company will announce its Full Year Results on 8th September 2015.
dreamcatcher
- 16 Jul 2015 18:11
- 44 of 99
16 Jul Investec 750.00 Buy
16 Jul Panmure Gordon 654.00 Hold
16 Jul Numis 590.00 Reduce
16 Jul Panmure Gordon 654.00 Hold
16 Jul Numis 590.00 Reduce
dreamcatcher
- 04 Sep 2015 16:12
- 45 of 99
Finals Tues 8 Sept
dreamcatcher
- 08 Sep 2015 17:07
- 46 of 99
Final Results
RNS
RNS Number : 3465Y
Craneware plc
08 September 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
8 September 2015 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its results for the year ended 30 June 2015.
Financial Highlights (US dollars)
· Total Contract Value in the year continues at record levels of $72.9m (FY14: $71.0m)
· Revenue increased to $44.8m (FY14: $42.6m)
· Adjusted EBITDA1. increased by 10% to $14.4m (FY14: $13.1m)
· Profit before tax increased to $12.5m (FY14: $11.3m)
· Basic adjusted EPS increased to $0.378 (FY14: $0.340) and adjusted diluted EPS has increased to $0.375 (FY14: $0.338)
· Positive operational cash flow of $22.0m (FY14: $10.2m)
· Cash at year end $41.8m (2014: $32.6m) after payment of $5.4m dividend to shareholders
· Proposed final dividend of 7.7p (12.1 cents) per share giving a total dividend for the year of 14.0p (22.0 cents) per share (2014: 12.5p (21.37 cents) per share)
1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
Operational Highlights
· US healthcare market evolving as predicted towards value-based care with a critical dependency on accurate financial data
· Launch of Craneware's Value Cycle strategy at HFMA ANI 2015
· Continued investment in the product suite and the development of a new fourth Gateway product in the Patient Access and consumerism market
· Data Analytics capability added through partnership
· Dollar renewal rates above 100%
· Total visible revenue increased to $123.4m (FY14 same 3 year period: $111.9m)
Keith Neilson, CEO of Craneware plc commented, "This year has seen Craneware continue its record level of sales, but perhaps more importantly has seen the anticipated emergence of a high growth financial analytics and performance market. Major changes in reimbursement and care delivery models have made understanding and reducing the cost of care mission-critical for every healthcare provider in the US. As we expand our offerings into this value-driven healthcare market and pioneer the Value Cycle, we are confident that our position as a trusted financial performance partner will strengthen. This provides a significant opportunity for the expansion of Craneware. This opportunity combined with the business' financial strength means we look to the future with confidence."
RNS
RNS Number : 3465Y
Craneware plc
08 September 2015
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
8 September 2015 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its results for the year ended 30 June 2015.
Financial Highlights (US dollars)
· Total Contract Value in the year continues at record levels of $72.9m (FY14: $71.0m)
· Revenue increased to $44.8m (FY14: $42.6m)
· Adjusted EBITDA1. increased by 10% to $14.4m (FY14: $13.1m)
· Profit before tax increased to $12.5m (FY14: $11.3m)
· Basic adjusted EPS increased to $0.378 (FY14: $0.340) and adjusted diluted EPS has increased to $0.375 (FY14: $0.338)
· Positive operational cash flow of $22.0m (FY14: $10.2m)
· Cash at year end $41.8m (2014: $32.6m) after payment of $5.4m dividend to shareholders
· Proposed final dividend of 7.7p (12.1 cents) per share giving a total dividend for the year of 14.0p (22.0 cents) per share (2014: 12.5p (21.37 cents) per share)
1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
Operational Highlights
· US healthcare market evolving as predicted towards value-based care with a critical dependency on accurate financial data
· Launch of Craneware's Value Cycle strategy at HFMA ANI 2015
· Continued investment in the product suite and the development of a new fourth Gateway product in the Patient Access and consumerism market
· Data Analytics capability added through partnership
· Dollar renewal rates above 100%
· Total visible revenue increased to $123.4m (FY14 same 3 year period: $111.9m)
Keith Neilson, CEO of Craneware plc commented, "This year has seen Craneware continue its record level of sales, but perhaps more importantly has seen the anticipated emergence of a high growth financial analytics and performance market. Major changes in reimbursement and care delivery models have made understanding and reducing the cost of care mission-critical for every healthcare provider in the US. As we expand our offerings into this value-driven healthcare market and pioneer the Value Cycle, we are confident that our position as a trusted financial performance partner will strengthen. This provides a significant opportunity for the expansion of Craneware. This opportunity combined with the business' financial strength means we look to the future with confidence."
dreamcatcher
- 08 Sep 2015 17:08
- 47 of 99
8 Sep Panmure Gordon 654.00 Hold
8 Sep Investec 750.00 Buy
8 Sep Investec 750.00 Buy
dreamcatcher
- 09 Nov 2015 16:23
- 48 of 99
Craneware PLC (CRW.GB:ISD) set a new 52-week high during today's trading session when it reached 779.00. Over this period, the share price is up 52.40%.
dreamcatcher
- 17 Nov 2015 17:38
- 49 of 99
AGM Statement
RNS
RNS Number : 9153F
Craneware plc
17 November 2015
Craneware plc
("Craneware" or the "Company")
AGM Statement
17 November 2015 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 9am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first few months of the year. In June, we launched the Value Cycle, our vision for the process and culture by which healthcare providers pursue quality patient outcomes and optimal financial performance within a healthcare market moving towards value-based care. Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.
This positive impact of the Value Cycle on the level of sales activity combined with the contribution of the prior year's sales flowing through to the current year financial results and the continued high levels of cash generation, mean we are well positioned to continue to execute on our growth strategy."
Craneware will be hosting an analyst and investor presentation at 11am today. The presentation to be given at the meeting will cover topics including the evolution of the US healthcare market towards value-based care, the escalation of patient engagement and consumerism, and the Value Cycle. The presentation will contain no new material information.
Copies of the presentation will be made available on the Company's website at www.craneware.com.
RNS
RNS Number : 9153F
Craneware plc
17 November 2015
Craneware plc
("Craneware" or the "Company")
AGM Statement
17 November 2015 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 9am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first few months of the year. In June, we launched the Value Cycle, our vision for the process and culture by which healthcare providers pursue quality patient outcomes and optimal financial performance within a healthcare market moving towards value-based care. Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.
This positive impact of the Value Cycle on the level of sales activity combined with the contribution of the prior year's sales flowing through to the current year financial results and the continued high levels of cash generation, mean we are well positioned to continue to execute on our growth strategy."
Craneware will be hosting an analyst and investor presentation at 11am today. The presentation to be given at the meeting will cover topics including the evolution of the US healthcare market towards value-based care, the escalation of patient engagement and consumerism, and the Value Cycle. The presentation will contain no new material information.
Copies of the presentation will be made available on the Company's website at www.craneware.com.
dreamcatcher
- 18 Nov 2015 19:15
- 50 of 99
Ex dividend 19 Nov 2015 Craneware PLC (7.7 P)
dreamcatcher
- 11 Jan 2016 07:42
- 51 of 99
11 Jan Peel Hunt 920.00 Buy
dreamcatcher
- 22 Jan 2016 11:10
- 52 of 99
Trading Update
RNS
RNS Number : 6501M
Craneware plc
22 January 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
22 January 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2015.
The Group is pleased to announce it has continued to perform strongly in the first half of the financial year. Ongoing sales success has delivered an increase of 15% in the value of 'new sales' contracts signed in the six month period ended 31 December 2015 compared to the same period last year and renewals by dollar value in the period have continued at over 100%. In accordance with the Company's revenue recognition policy the majority of revenue resulting from these sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
As a result, the Group expects to report an increase of over 10% in adjusted EBITDA for the six months ended 31 December 2015 and a 7% increase in recognised revenue, compared with the same period last year.
High levels of cash generation in the period have resulted in cash reserves of $45m (H115:$41.8m). In addition, the Group has secured a funding facility from the Bank of Scotland of up to $50m. This will be available to the Group as it continues to investigate strategic opportunities to further expand its Value Cycle solution.
With growth in the period in line with management's expectations, high levels of cash generation and the continued sales momentum, the Board is confident in meeting market expectations for the full year.
The Company will announce results for the six months ended 31 December 2015 on 8 March 2016.
Keith Neilson, CEO of Craneware plc commented, "We are seeing the initial success of the 'Value Cycle', our vision for the process and culture by which US healthcare providers pursue quality patient outcomes and optimal financial performance, in our continued strong sales performance.
The Group's strong financial position allows us to evaluate our options as we look to enhance and add solutions which support our customers in the new Value-based reimbursement environment.
These factors combined with revenue recognition from contracted sales made in prior periods, gives management confidence in its ability to deliver increasing stakeholder value through this year and in the future
RNS
RNS Number : 6501M
Craneware plc
22 January 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
22 January 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2015.
The Group is pleased to announce it has continued to perform strongly in the first half of the financial year. Ongoing sales success has delivered an increase of 15% in the value of 'new sales' contracts signed in the six month period ended 31 December 2015 compared to the same period last year and renewals by dollar value in the period have continued at over 100%. In accordance with the Company's revenue recognition policy the majority of revenue resulting from these sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
As a result, the Group expects to report an increase of over 10% in adjusted EBITDA for the six months ended 31 December 2015 and a 7% increase in recognised revenue, compared with the same period last year.
High levels of cash generation in the period have resulted in cash reserves of $45m (H115:$41.8m). In addition, the Group has secured a funding facility from the Bank of Scotland of up to $50m. This will be available to the Group as it continues to investigate strategic opportunities to further expand its Value Cycle solution.
With growth in the period in line with management's expectations, high levels of cash generation and the continued sales momentum, the Board is confident in meeting market expectations for the full year.
The Company will announce results for the six months ended 31 December 2015 on 8 March 2016.
Keith Neilson, CEO of Craneware plc commented, "We are seeing the initial success of the 'Value Cycle', our vision for the process and culture by which US healthcare providers pursue quality patient outcomes and optimal financial performance, in our continued strong sales performance.
The Group's strong financial position allows us to evaluate our options as we look to enhance and add solutions which support our customers in the new Value-based reimbursement environment.
These factors combined with revenue recognition from contracted sales made in prior periods, gives management confidence in its ability to deliver increasing stakeholder value through this year and in the future
dreamcatcher
- 22 Jan 2016 11:11
- 53 of 99
22 Jan Investec 915.00 Buy
22 Jan Peel Hunt 920.00 Buy
22 Jan Peel Hunt 920.00 Buy
dreamcatcher
- 02 Feb 2016 16:37
- 54 of 99
Significant Contract Win and Reseller Agreement
RNS
RNS Number : 7165N
Craneware plc
02 February 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win and Reseller Agreement
2 February 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a hospital operator in the US. The Company is also pleased to announce the signing of an exclusive value added reseller agreement with US-based automated payment technologies and services company, VestaCare. The Company will combine VestaCare's proprietary technology with its own to offer accelerated payment and patient engagement solutions.
Contract win
The contract is expected to deliver $7.5m revenue over the initial five year term. The new customer is a growing hospital operator and consolidator that manages in excess of 50 hospitals across multiple US states primarily in non-urban communities. Under the terms of the contract, Craneware will deliver its Chargemaster Corporate Toolkit® to establish and manage corporate standardisation across its entire portfolio of owned and managed facilities. This will enable system wide reporting efficiencies and the timely submission of accurate claims whilst managing billing compliance risk.
The Company's revenue recognition policy means that the full impact of the revenue generated from this contract will be seen from FY17 onwards.
Reseller agreement
Under the new reseller agreement, VestaCare's VestaPay technology will be integrated with Craneware's medical necessity and price estimation products, to deliver enhanced Patient Engagement solutions, a key element of Craneware's product roadmap. These will be delivered via Craneware's mobile patient engagement platform, which has been developed following the acquisition of Kestros in 2014. The enhanced solutions will help providers better address the financial risks associated with the rapidly changing role of patient financial responsibility in the era of the Value Cycle. By integrating with providers' financial systems to adjust patients' outstanding balances on their accounts in real time, providers can offer the individual a compassionate, flexible program of repayments to address patient responsibility, dramatically reducing the hospitals' exposure to "self-pay" debt. In addition, providers benefit from improved patient satisfaction, better pricing transparency and accelerated revenue. Craneware will receive an annual license fee from customers with an additional revenue share agreement based on patient collection improvements.
Keith Neilson, CEO of Craneware plc, commented, "Both of these agreements not only provide Craneware with significant future revenue opportunities but also further enhance the Company's strategic value to customers. We are delighted to sign a significant new customer, which is testament to our position as a trusted partner for US healthcare organisations. The new reseller agreement deepens our reach within the early stages of patient engagement and demonstrates our leadership in the evolving market of value-based care and patient responsibility."
RNS
RNS Number : 7165N
Craneware plc
02 February 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win and Reseller Agreement
2 February 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a hospital operator in the US. The Company is also pleased to announce the signing of an exclusive value added reseller agreement with US-based automated payment technologies and services company, VestaCare. The Company will combine VestaCare's proprietary technology with its own to offer accelerated payment and patient engagement solutions.
Contract win
The contract is expected to deliver $7.5m revenue over the initial five year term. The new customer is a growing hospital operator and consolidator that manages in excess of 50 hospitals across multiple US states primarily in non-urban communities. Under the terms of the contract, Craneware will deliver its Chargemaster Corporate Toolkit® to establish and manage corporate standardisation across its entire portfolio of owned and managed facilities. This will enable system wide reporting efficiencies and the timely submission of accurate claims whilst managing billing compliance risk.
The Company's revenue recognition policy means that the full impact of the revenue generated from this contract will be seen from FY17 onwards.
Reseller agreement
Under the new reseller agreement, VestaCare's VestaPay technology will be integrated with Craneware's medical necessity and price estimation products, to deliver enhanced Patient Engagement solutions, a key element of Craneware's product roadmap. These will be delivered via Craneware's mobile patient engagement platform, which has been developed following the acquisition of Kestros in 2014. The enhanced solutions will help providers better address the financial risks associated with the rapidly changing role of patient financial responsibility in the era of the Value Cycle. By integrating with providers' financial systems to adjust patients' outstanding balances on their accounts in real time, providers can offer the individual a compassionate, flexible program of repayments to address patient responsibility, dramatically reducing the hospitals' exposure to "self-pay" debt. In addition, providers benefit from improved patient satisfaction, better pricing transparency and accelerated revenue. Craneware will receive an annual license fee from customers with an additional revenue share agreement based on patient collection improvements.
Keith Neilson, CEO of Craneware plc, commented, "Both of these agreements not only provide Craneware with significant future revenue opportunities but also further enhance the Company's strategic value to customers. We are delighted to sign a significant new customer, which is testament to our position as a trusted partner for US healthcare organisations. The new reseller agreement deepens our reach within the early stages of patient engagement and demonstrates our leadership in the evolving market of value-based care and patient responsibility."
dreamcatcher
- 08 Mar 2016 08:20
- 55 of 99
Half yearly report
Financial Highlights (US dollars)
· Value of 'new sales' contracts signed in the period increased 15% compared to H1 2015
· Revenue increased 7% to $23.1m (H1 2015: $21.6m)
· Adjusted EBITDA1 increased 12% to $7.1m (H1 2015: $6.3m)
· Profit before tax increased 15% to $6.1m (H1 2015: $5.3m)
· Adjusted basic EPS increased 14% to 18.8 cents per share (H1 2015: 16.5 cents per share)
· Cash at period end increased 24% to $45m (H1 2015: $36.4m)
· Proposed interim dividend increased 19% to 7.5p (H1 2015: 6.3p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
· Continued sales momentum and record pipeline
· Positive industry response to the Value Cycle
· Chargemaster Toolkit named Best in Klas for the 10th consecutive year in "2016 Best in KLAS Awards"
· Pharmacy ChargeLink, now selling 1:1 with Chargemaster Toolkit
· Progress on delivering Trisus product roadmap:
o Development of Patient Engagement and Access gateway product on track
o Reseller agreement signed post half-year end with US based VestaCare, an automated payment technologies and services company to offer accelerated payment and patient engagement solutions
· $7.5m contract win signed post half year end with an operator of 50 US hospitals
Financial Highlights (US dollars)
· Value of 'new sales' contracts signed in the period increased 15% compared to H1 2015
· Revenue increased 7% to $23.1m (H1 2015: $21.6m)
· Adjusted EBITDA1 increased 12% to $7.1m (H1 2015: $6.3m)
· Profit before tax increased 15% to $6.1m (H1 2015: $5.3m)
· Adjusted basic EPS increased 14% to 18.8 cents per share (H1 2015: 16.5 cents per share)
· Cash at period end increased 24% to $45m (H1 2015: $36.4m)
· Proposed interim dividend increased 19% to 7.5p (H1 2015: 6.3p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
· Continued sales momentum and record pipeline
· Positive industry response to the Value Cycle
· Chargemaster Toolkit named Best in Klas for the 10th consecutive year in "2016 Best in KLAS Awards"
· Pharmacy ChargeLink, now selling 1:1 with Chargemaster Toolkit
· Progress on delivering Trisus product roadmap:
o Development of Patient Engagement and Access gateway product on track
o Reseller agreement signed post half-year end with US based VestaCare, an automated payment technologies and services company to offer accelerated payment and patient engagement solutions
· $7.5m contract win signed post half year end with an operator of 50 US hospitals
dreamcatcher
- 08 Mar 2016 08:26
- 56 of 99
8 Mar Peel Hunt 920.00 Buy
dreamcatcher
- 18 Mar 2016 14:03
- 57 of 99
Dividend Currency Election
RNS
RNS Number : 5736S
Craneware plc
18 March 2016
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
18 March 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its interim dividend announced on 8 March 2016.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.42/ £1.
RNS
RNS Number : 5736S
Craneware plc
18 March 2016
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
18 March 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its interim dividend announced on 8 March 2016.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.42/ £1.
dreamcatcher
- 28 Apr 2016 18:05
- 58 of 99
28 Apr Peel Hunt 920.00 Buy
dreamcatcher
- 06 Jul 2016 20:26
- 59 of 99
Trading Update, Contract Win and Notice of Results
RNS
RNS Number : 3413D
Craneware plc
06 July 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update, Significant Contract win and Notice of Results
6 July 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2016.
The Board is pleased to confirm the Group's third consecutive year of record sales performance and a return to double digit growth at the revenue and adjusted EBITDA level.
The Group has seen greater than 60% growth in the value of 'New Sales' contracts signed of c$58m (2015 $35.9m) with the average new contract length being maintained at 5 years.
Included in the year's sales success are two significant contracts. The first announced on 2 February 2016 was for a 50 hospital group in excess of $7.5m revenue over its five year life. In addition to this the Company is pleased to announce that it finished the year with a further multi-hospital group contract win. Starting in FY17, the contract is expected to deliver revenue greater than $8m during the next five years, as the hospital network rolls out multiple Craneware core value cycle solutions.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from all sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract. Accordingly the Group expects to report an increase of 11% in revenues and 10% in adjusted EBITDA for the year ended 30 June 2016.
Other key performance indicators continue to be positive. The Group continued to renew hospitals that were due for renewal in the year at an average of above 100% (by $ value) and customer retention continues to be significantly higher than the industry norm.
Strong cash generation resulted in cash reserves in excess of $47m at 30 June 2016 (2015 $41.8m).
Keith Neilson, CEO of Craneware plc commented, "US Healthcare providers continue to address the challenges the new value based re-imbursement environment brings. We believe our continued sales growth demonstrates the strategic importance of Craneware and its Value Cycle solutions to them as they meet these challenges. The ongoing investment we are making to develop solutions that discover, convert and optimise value for healthcare providers, combined with our own historical sales successes, double digit revenue and adjusted EBITDA growth, give management confidence in its ability to deliver continued future growth as well as increasing stakeholder value."
The Company will announce its Full Year Results on 6 September 2016.
dreamcatcher
- 06 Jul 2016 20:32
- 60 of 99
6 Jul Peel Hunt 920.00 Buy
dreamcatcher
- 21 Jul 2016 18:41
- 61 of 99
Craneware PLC (CRW:LSE) set a new 52-week high during Wednesday's trading session when it reached 895.00. Over this period, the share price is up 44.44%.
dreamcatcher
- 25 Aug 2016 07:07
- 62 of 99
25 Aug Peel Hunt 1,335.00 Buy
dreamcatcher
- 06 Sep 2016 18:48
- 63 of 99
Final Results
RNS
RNS Number : 0121J
Craneware plc
06 September 2016
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
6 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2016.
Financial Highlights (US dollars)
•Total Contract Value in the year continues at record levels of $82.3m (FY15: $72.9m) ◦new sales increased by 63% to $58.6m (FY15: $35.9m)
◦renewal rate remains above 100% by dollar value
•Revenue increased 11% to $49.8m (FY15: $44.8m)
•Adjusted EBITDA1. increased by 10% to $15.9m (FY15: $14.4m)
•Profit before tax increased by 10% to $13.9m (FY15: $12.5m)
•Basic adjusted EPS increased 13% to $0.429 (FY15: $0.378) and adjusted diluted EPS has increased to $0.423 (FY15: $0.375)
•Continued operating cash conversion above 100% of Adjusted EBITDA
•Cash at year-end of $48.8m (FY15: $41.8m) after payment of $6m dividend to shareholders
•Proposed final dividend of 9p (12 cents) per share giving a total dividend for the year of 16.5p (22 cents) per share (FY15: 14p (22 cents) per share)
1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
Operational Highlights (Finals)
•US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data
•Further expansion of the product suite to support the Value Cycle, including: ◦development of Trisus Patient Payment Module, our Patient Engagement and Access gateway product, on track for launch during calendar 2016
◦launch of Craneware Healthcare Intelligence, a new group business, developing new solutions to address an emerging but significant market opportunity for healthcare cost analytics
•Two significant 5 year contract wins in the year for Craneware core value cycle solutions, worth a combined $15.5m
•Continued very high levels of customer retention
•Total visible revenue increased 23% to $149.1m (FY15 same 3 year period: $121.1m)
Keith Neilson, CEO of Craneware plc commented, "Craneware is in a stronger position than ever and we are passionate about the opportunity ahead. The double digit growth in our reported revenue and adjusted EBITDA are only beginning to reflect the record levels of sales which began three years ago. Importantly, the investment we are making in our product suite mean our market opportunity is now several times larger than it was when we joined AIM in 2007.
"The market continues to evolve as we anticipated. US healthcare providers are seeking the solutions to address the challenges the new value based re-imbursement environment brings to them. We believe the investment we are making to expand the products in our Value Cycle suite addresses these challenges and we are now recognised beyond our original niche within the revenue cycle as a more strategic provider within a hospital's financial operations and their value cycle.
"We are confident that the ongoing investment we are making, combined with our continuing sales successes, mean we are well positioned to deliver continued future growth as well as increasing stakeholder value."
dreamcatcher
- 09 Sep 2016 15:40
- 64 of 99
New high.
dreamcatcher
- 20 Sep 2016 07:05
- 65 of 99
Director/PDMR Shareholding
RNS
RNS Number : 2394K
Craneware plc
20 September 2016
Craneware plc
("Craneware" or the "Company")
Director Shareholding
20 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, has been informed that Keith Neilson, CEO of the Company, yesterday purchased 5,388 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 1,200 pence per share.
Following this transaction, Mr. Neilson's beneficial interest in Craneware has increased to 3,509,518 Ordinary Shares, representing approximately 13.1% of the Company's issued Ordinary Share capital.
RNS
RNS Number : 2394K
Craneware plc
20 September 2016
Craneware plc
("Craneware" or the "Company")
Director Shareholding
20 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, has been informed that Keith Neilson, CEO of the Company, yesterday purchased 5,388 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 1,200 pence per share.
Following this transaction, Mr. Neilson's beneficial interest in Craneware has increased to 3,509,518 Ordinary Shares, representing approximately 13.1% of the Company's issued Ordinary Share capital.
dreamcatcher
- 08 Nov 2016 07:06
- 66 of 99
AGM Statement
RNS
RNS Number : 5525O
Craneware plc
08 November 2016
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
8 November 2016 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 10am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We continue to see positive results in the first few months of the current fiscal year. In September we announced the move back into double-digit revenue and adjusted EBITDA growth. With the impact of sales made during FY16 starting to contribute to revenue, combined with our sales pipeline and activity, we see that momentum continuing in the current year.
"The US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data. We are investing in our Value Cycle product suite to ensure we have the solutions to provide hospitals with tools that deliver insight into these areas of their operations, expanding our market opportunity and increasing our strategic value within our market.
"2017 will see some exciting developments for Craneware with the launch of Trisus Claims Informatics, the first product to be launched on our newly developed cloud-based Trisus Enterprise Value Platform; followed shortly thereafter by the launch of Trisus Patient Payment, a new fourth gateway product, operating within the patient access and engagement area.
"We are also making good progress within our newly formed Group business, Craneware Healthcare Intelligence, which is focused on the development of cost analytics software for the US healthcare industry.
"With our expanded offering and market opportunity, high levels of revenue visibility and favourable market backdrop, we believe we are just at the start of a long-term growth trajectory and are confident in the future success of Craneware."
RNS
RNS Number : 5525O
Craneware plc
08 November 2016
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
8 November 2016 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 10am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We continue to see positive results in the first few months of the current fiscal year. In September we announced the move back into double-digit revenue and adjusted EBITDA growth. With the impact of sales made during FY16 starting to contribute to revenue, combined with our sales pipeline and activity, we see that momentum continuing in the current year.
"The US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data. We are investing in our Value Cycle product suite to ensure we have the solutions to provide hospitals with tools that deliver insight into these areas of their operations, expanding our market opportunity and increasing our strategic value within our market.
"2017 will see some exciting developments for Craneware with the launch of Trisus Claims Informatics, the first product to be launched on our newly developed cloud-based Trisus Enterprise Value Platform; followed shortly thereafter by the launch of Trisus Patient Payment, a new fourth gateway product, operating within the patient access and engagement area.
"We are also making good progress within our newly formed Group business, Craneware Healthcare Intelligence, which is focused on the development of cost analytics software for the US healthcare industry.
"With our expanded offering and market opportunity, high levels of revenue visibility and favourable market backdrop, we believe we are just at the start of a long-term growth trajectory and are confident in the future success of Craneware."
dreamcatcher
- 10 Nov 2016 16:00
- 67 of 99
10 Nov
Peel Hunt
1,335.00
Buy
Peel Hunt
1,335.00
Buy
dreamcatcher
- 17 Jan 2017 07:05
- 68 of 99
Trading Update
RNS
RNS Number : 2943U
Craneware plc
17 January 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
17 January 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2016.
The Group is pleased to announce continued growth and expects to report 15% increases in both revenue and adjusted EBITDA for the six month period ended 31 December 2016, building on the return to double digit growth reported in the year to 30 June 2016 and slightly ahead of expectations.
Underlying sales continue to support this growth, with a particularly strong Q2, post the US Election result, and a healthy sales pipeline. In accordance with the Company's revenue recognition policy the vast majority of revenue resulting from sales made in the period will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
The Group continues to invest for the future. In the period it has invested c$3m in its newly formed Employee Benefit trust and over $1.0m in future product development, including its cloud-based Trisus product suite and the new Craneware Healthcare Intelligence product suite.
The Group's cash balance at the end of the period was maintained at $45m (H116: $45m) after making these investments whilst continuing a progressive dividend payment policy. In addition, the Group retains an available funding facility from the Bank of Scotland of up to $50m as it continues to investigate strategic opportunities to further expand its Value Cycle solution.
With the growth in the period, continued cash generation and a healthy sales pipeline, the Board is confident in meeting market expectations for the full year.
The Company will announce its results for the six months ended 31 December 2016 on 7 March 2017.
Keith Neilson, CEO of Craneware plc commented, "There is continued consensus in the US of the need to drive value in Healthcare with ongoing support for the move to value-based care and increasing consumerism. An impending change of government always brings with it an element of uncertainty, it was therefore particularly pleasing to see the acceleration in sales of our Value Cycle solutions post the result of the US Presidential election. Our Value Cycle software continues to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes.
"We continue to invest in both our current solutions and in the new products we are developing to expand our support to US Healthcare providers as they pursue quality patient outcomes and optimal financial performance.
"These supportive market drivers, our investment for the future and our continued profitable growth, give management confidence in its ability to deliver continued stakeholder value."
RNS
RNS Number : 2943U
Craneware plc
17 January 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update
17 January 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2016.
The Group is pleased to announce continued growth and expects to report 15% increases in both revenue and adjusted EBITDA for the six month period ended 31 December 2016, building on the return to double digit growth reported in the year to 30 June 2016 and slightly ahead of expectations.
Underlying sales continue to support this growth, with a particularly strong Q2, post the US Election result, and a healthy sales pipeline. In accordance with the Company's revenue recognition policy the vast majority of revenue resulting from sales made in the period will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
The Group continues to invest for the future. In the period it has invested c$3m in its newly formed Employee Benefit trust and over $1.0m in future product development, including its cloud-based Trisus product suite and the new Craneware Healthcare Intelligence product suite.
The Group's cash balance at the end of the period was maintained at $45m (H116: $45m) after making these investments whilst continuing a progressive dividend payment policy. In addition, the Group retains an available funding facility from the Bank of Scotland of up to $50m as it continues to investigate strategic opportunities to further expand its Value Cycle solution.
With the growth in the period, continued cash generation and a healthy sales pipeline, the Board is confident in meeting market expectations for the full year.
The Company will announce its results for the six months ended 31 December 2016 on 7 March 2017.
Keith Neilson, CEO of Craneware plc commented, "There is continued consensus in the US of the need to drive value in Healthcare with ongoing support for the move to value-based care and increasing consumerism. An impending change of government always brings with it an element of uncertainty, it was therefore particularly pleasing to see the acceleration in sales of our Value Cycle solutions post the result of the US Presidential election. Our Value Cycle software continues to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes.
"We continue to invest in both our current solutions and in the new products we are developing to expand our support to US Healthcare providers as they pursue quality patient outcomes and optimal financial performance.
"These supportive market drivers, our investment for the future and our continued profitable growth, give management confidence in its ability to deliver continued stakeholder value."
dreamcatcher
- 17 Jan 2017 17:00
- 69 of 99
17 Jan
Peel Hunt
1,335.00
Buy
Peel Hunt
1,335.00
Buy
dreamcatcher
- 07 Mar 2017 07:05
- 70 of 99
Half-year Report
RNS
RNS Number : 6750Y
Craneware plc
07 March 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Interim Results
7 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2016.
Financial Highlights (US dollars)
Revenue increased 16% to $26.8m (H1 2016: $23.1m)
Adjusted EBITDA1 increased 16% to $8.2m (H1 2016: $7.1m)
Profit before tax increased 23% to $7.5m (H1 2016: $6.1m)
Adjusted basic EPS increased 15% to 21.6 cents per share (H1 2016: 18.8 cents per share)
Strong cash position maintained at $45m (H1 2016: $45m) following dividend payment of $3.2m and investments of $4.5m made during the period
Proposed interim dividend increased 16% to 8.7p (H1 2016: 7.5p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
Consensus for the need to drive value in US Healthcare provides supportive market dynamics
Continued growth supported by underlying sales and sales pipelines
Expansion of the Value Cycle solution suite on track with initial components of the cloud-based Trisus Enterprise Value Platform being rolled out during the calendar year
Positive progress with Craneware Healthcare Intelligence, a new solution set developed to address the significant market opportunity for healthcare cost analytics
Total visible revenue of over $55.4m for the current year and $155.5m for the three year period to June 2019 (H1 2016 same three year period: $128.1m)
Board confident in outlook for the year
Keith Neilson, CEO of Craneware plc commented, "The first half of the year has been a period of successful execution against our stated growth strategy, delivering accelerated growth at both the revenue and adjusted EBITDA level. During the period we have taken significant strides forward in terms of delivering our expanded product suite, educating our market place and also further investing in our people. These ongoing achievements mean we are well positioned to deliver against a market opportunity that is now considerably larger than at any other point in our history.
"Against a backdrop of the recent US Presidential election, the overriding consensus for the need to drive value in US Healthcare has been re-affirmed. There is ongoing support for the move to value-based care and increasing consumerism. Our Value Cycle software suite will continue to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes.
"These supportive market drivers, our investment for the future and our continued profitable growth give us confidence in continuing to deliver value for our stakeholders."
RNS
RNS Number : 6750Y
Craneware plc
07 March 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Interim Results
7 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2016.
Financial Highlights (US dollars)
Revenue increased 16% to $26.8m (H1 2016: $23.1m)
Adjusted EBITDA1 increased 16% to $8.2m (H1 2016: $7.1m)
Profit before tax increased 23% to $7.5m (H1 2016: $6.1m)
Adjusted basic EPS increased 15% to 21.6 cents per share (H1 2016: 18.8 cents per share)
Strong cash position maintained at $45m (H1 2016: $45m) following dividend payment of $3.2m and investments of $4.5m made during the period
Proposed interim dividend increased 16% to 8.7p (H1 2016: 7.5p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
Consensus for the need to drive value in US Healthcare provides supportive market dynamics
Continued growth supported by underlying sales and sales pipelines
Expansion of the Value Cycle solution suite on track with initial components of the cloud-based Trisus Enterprise Value Platform being rolled out during the calendar year
Positive progress with Craneware Healthcare Intelligence, a new solution set developed to address the significant market opportunity for healthcare cost analytics
Total visible revenue of over $55.4m for the current year and $155.5m for the three year period to June 2019 (H1 2016 same three year period: $128.1m)
Board confident in outlook for the year
Keith Neilson, CEO of Craneware plc commented, "The first half of the year has been a period of successful execution against our stated growth strategy, delivering accelerated growth at both the revenue and adjusted EBITDA level. During the period we have taken significant strides forward in terms of delivering our expanded product suite, educating our market place and also further investing in our people. These ongoing achievements mean we are well positioned to deliver against a market opportunity that is now considerably larger than at any other point in our history.
"Against a backdrop of the recent US Presidential election, the overriding consensus for the need to drive value in US Healthcare has been re-affirmed. There is ongoing support for the move to value-based care and increasing consumerism. Our Value Cycle software suite will continue to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes.
"These supportive market drivers, our investment for the future and our continued profitable growth give us confidence in continuing to deliver value for our stakeholders."
dreamcatcher
- 07 Mar 2017 18:10
- 71 of 99
7 Mar
Peel Hunt
1,450.00
Buy
Peel Hunt
1,450.00
Buy
dreamcatcher
- 23 Mar 2017 20:50
- 72 of 99
Significant Contract Win
RNS
RNS Number : 2611A
Craneware plc
23 March 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win
23 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a large hospital operator in the US.
This win, with an existing customer, adds further Value Cycle solutions and related services to a seven year contract originally announced in April 2014. The contract is expected to deliver a further $3.7m of revenue over this new seven year term as the hospital network rolls out these additional solutions across its facilities and $1.5m of additional revenue as the contract for the currently implemented solutions is extended to run co-terminus to this amendment.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
Keith Neilson, CEO of Craneware plc, commented, "The strategic importance of Craneware's Value Cycle solutions allow us to add new customers and deepen our relationship with our existing customers as both groups address the challenges resulting from the continued evolution to the new value based re-imbursement environment. The extension of the solution set provided to this customer and increasing the duration of the original contract underlines the value our solutions bring to our customers. We have a very positive relationship with our customers, demonstrating sustainable value; we now look forward to this extension of our working relationship with this customer to over a decade."
RNS
RNS Number : 2611A
Craneware plc
23 March 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win
23 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a large hospital operator in the US.
This win, with an existing customer, adds further Value Cycle solutions and related services to a seven year contract originally announced in April 2014. The contract is expected to deliver a further $3.7m of revenue over this new seven year term as the hospital network rolls out these additional solutions across its facilities and $1.5m of additional revenue as the contract for the currently implemented solutions is extended to run co-terminus to this amendment.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
Keith Neilson, CEO of Craneware plc, commented, "The strategic importance of Craneware's Value Cycle solutions allow us to add new customers and deepen our relationship with our existing customers as both groups address the challenges resulting from the continued evolution to the new value based re-imbursement environment. The extension of the solution set provided to this customer and increasing the duration of the original contract underlines the value our solutions bring to our customers. We have a very positive relationship with our customers, demonstrating sustainable value; we now look forward to this extension of our working relationship with this customer to over a decade."
dreamcatcher
- 26 Apr 2017 16:36
- 73 of 99
26 Apr
Peel Hunt
1,450.00
Buy
Peel Hunt
1,450.00
Buy
dreamcatcher
- 11 Jul 2017 20:49
- 74 of 99
08:00 11/07/2017
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 1495p (from 1450p). Story provided by StockMarketWire.com
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 1495p (from 1450p). Story provided by StockMarketWire.com
dreamcatcher
- 05 Sep 2017 16:50
- 75 of 99
Final Results
RNS
RNS Number : 7912P
Craneware plc
05 September 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
Double digit revenue and profit growth and successful transition into execution phase of the growth strategy
5 September 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2017.
Financial Highlights (US dollars)
· Revenue increased 16% to $57.8m (FY16: $49.8m)
· Adjusted EBITDA1. increased 13% to $18.0m (FY16: $15.9m)
· Profit before tax increased 22% to $16.9m (FY16: $13.9m)
· Basic adjusted EPS increased 20% to $0.514 (FY16: $0.429) and adjusted diluted EPS increased to $0.503 (FY16: $0.423)
· Total visible revenue increased 13% to $163.8m (FY16 same 3 year period: $145.3m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Cash at year-end of $53.2m (FY16: $48.8m) after payment of $6.4m dividend to shareholders and increased investment of over $3.0m in R&D
· Proposed final dividend of 11.3p (14.71 cents) per share giving a total dividend for the year of 20.0p (26.04 cents) per share (FY16: 16.5p (22 cents) per share)
· Renewal rate remains above 100% by dollar value
1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
Operational Highlights
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Successful launch of cloud-based Trisus™ platform, with extremely positive customer response
· Initial sales of Trisus Claims Informatics™, the first product on the Trisus™ platform
· Early adopters secured for Craneware Healthcare Intelligence, the Group's new business focused on healthcare Cost Analytics and Resource Efficiency (CARE)
· Record sales pipeline for the current financial year
Keith Neilson, CEO of Craneware plc commented, "We are delighted to report that, with record levels of revenue and profitability, the launch of our Trisus platform with secured sales for the first Trisus product (Trisus Claims Informatics™), and the launch of Craneware Healthcare Intelligence, this was the year in which we saw our unique vision of the Value Cycle, turn from concept to reality.
"While laying out our vision for the Value Cycle over the last two years, Craneware has delivered double digit growth in our key metrics, including revenue and profit, supported by sales success throughout the period. We have expanded our product suite into the Value Cycle; developed a new cloud-based technology platform, Trisus; and created a new Group business, Craneware Healthcare Intelligence, all significantly increasing the Company's total addressable market. At the same time we have been investing in improving our customers' experience and have returned in excess of $15m to shareholders by way of dividends and share buy backs.
"The unceasing evolution of the US healthcare market towards value-based care presents us with an ongoing, growing market opportunity and the investments we have made mean we now have the potential to deliver against this expanding opportunity. With our sales pipeline increasing each year, this increased scalability and opportunity, combined with our high levels of revenue visibility, strong cash position and extensive customer base provide us with confidence in Craneware's ongoing success."
RNS
RNS Number : 7912P
Craneware plc
05 September 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
Double digit revenue and profit growth and successful transition into execution phase of the growth strategy
5 September 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2017.
Financial Highlights (US dollars)
· Revenue increased 16% to $57.8m (FY16: $49.8m)
· Adjusted EBITDA1. increased 13% to $18.0m (FY16: $15.9m)
· Profit before tax increased 22% to $16.9m (FY16: $13.9m)
· Basic adjusted EPS increased 20% to $0.514 (FY16: $0.429) and adjusted diluted EPS increased to $0.503 (FY16: $0.423)
· Total visible revenue increased 13% to $163.8m (FY16 same 3 year period: $145.3m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Cash at year-end of $53.2m (FY16: $48.8m) after payment of $6.4m dividend to shareholders and increased investment of over $3.0m in R&D
· Proposed final dividend of 11.3p (14.71 cents) per share giving a total dividend for the year of 20.0p (26.04 cents) per share (FY16: 16.5p (22 cents) per share)
· Renewal rate remains above 100% by dollar value
1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
Operational Highlights
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Successful launch of cloud-based Trisus™ platform, with extremely positive customer response
· Initial sales of Trisus Claims Informatics™, the first product on the Trisus™ platform
· Early adopters secured for Craneware Healthcare Intelligence, the Group's new business focused on healthcare Cost Analytics and Resource Efficiency (CARE)
· Record sales pipeline for the current financial year
Keith Neilson, CEO of Craneware plc commented, "We are delighted to report that, with record levels of revenue and profitability, the launch of our Trisus platform with secured sales for the first Trisus product (Trisus Claims Informatics™), and the launch of Craneware Healthcare Intelligence, this was the year in which we saw our unique vision of the Value Cycle, turn from concept to reality.
"While laying out our vision for the Value Cycle over the last two years, Craneware has delivered double digit growth in our key metrics, including revenue and profit, supported by sales success throughout the period. We have expanded our product suite into the Value Cycle; developed a new cloud-based technology platform, Trisus; and created a new Group business, Craneware Healthcare Intelligence, all significantly increasing the Company's total addressable market. At the same time we have been investing in improving our customers' experience and have returned in excess of $15m to shareholders by way of dividends and share buy backs.
"The unceasing evolution of the US healthcare market towards value-based care presents us with an ongoing, growing market opportunity and the investments we have made mean we now have the potential to deliver against this expanding opportunity. With our sales pipeline increasing each year, this increased scalability and opportunity, combined with our high levels of revenue visibility, strong cash position and extensive customer base provide us with confidence in Craneware's ongoing success."
dreamcatcher
- 05 Sep 2017 16:53
- 76 of 99
5 Sep
Peel Hunt
1,495.00
Buy
Peel Hunt
1,495.00
Buy
T110Mikey - 06 Sep 2017 08:42 - 77 of 99
Anyone subscribing to the MoneyAM Level 2 platform please take note that most days it is not reporting the correct Trade High nor Trade Low information and "some days" not reporting the correct Opening Price or Closing Price.
The reason is because MoneyAM's Level 2 system is not correctly sensing the Auto Trades or Ordinary Trades correctly so is wrongly reporting them
The reason is because MoneyAM's Level 2 system is not correctly sensing the Auto Trades or Ordinary Trades correctly so is wrongly reporting them
dreamcatcher
- 12 Oct 2017 18:39
- 78 of 99
Craneware shareholders approve 11.3p final divi
StockMarketWire.com
Craneware has confirmed that shareholders approved the proposed final dividend of 11.3p per share at today's Annual General Meeting, taking the total dividend for the year to 20p.
The final dividend will be paid on 7 December to shareholders on the register as at 10 November, with a corresponding ex-Dividend date of 9 November.
At 1:14pm: (LON:CRW) Craneware PLC share price was +10p at 1325p
Story provided by StockMarketWire.com
StockMarketWire.com
Craneware has confirmed that shareholders approved the proposed final dividend of 11.3p per share at today's Annual General Meeting, taking the total dividend for the year to 20p.
The final dividend will be paid on 7 December to shareholders on the register as at 10 November, with a corresponding ex-Dividend date of 9 November.
At 1:14pm: (LON:CRW) Craneware PLC share price was +10p at 1325p
Story provided by StockMarketWire.com
dreamcatcher
- 31 Oct 2017 16:44
- 79 of 99
Significant Contract Win
RNS
RNS Number : 0253V
Craneware plc
31 October 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win
31 October 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce the renewal and significant expansion of an existing contract with a growing hospital operator in the US.
This $6m win sees the extension of a relationship that has been in place since 2007, with the renewal of the customer's existing Value Cycle solutions and the roll out of these same solutions to further facilities that have been recently acquired by this hospital network. The contract is expected to deliver $3.5m of incremental revenue over this new five year term as the hospital network rolls out these solutions at its additional facilities.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
Keith Neilson, CEO of Craneware plc, commented, "The expansion of this relationship demonstrates the strategic importance of Craneware's Value Cycle solutions to our customers, as they extend their own hospital networks throughout the US. The strength of our solutions and the value they deliver to all customers, including large and complex health systems, allows us to deepen our relationship with our customers as they address the challenges resulting from the continued evolution to the new value based re-imbursement environment.
"Having enjoyed our positive working relationship for a decade, we now look forward to continuing to deliver sustainable value throughout this new term."
RNS
RNS Number : 0253V
Craneware plc
31 October 2017
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Win
31 October 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce the renewal and significant expansion of an existing contract with a growing hospital operator in the US.
This $6m win sees the extension of a relationship that has been in place since 2007, with the renewal of the customer's existing Value Cycle solutions and the roll out of these same solutions to further facilities that have been recently acquired by this hospital network. The contract is expected to deliver $3.5m of incremental revenue over this new five year term as the hospital network rolls out these solutions at its additional facilities.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
Keith Neilson, CEO of Craneware plc, commented, "The expansion of this relationship demonstrates the strategic importance of Craneware's Value Cycle solutions to our customers, as they extend their own hospital networks throughout the US. The strength of our solutions and the value they deliver to all customers, including large and complex health systems, allows us to deepen our relationship with our customers as they address the challenges resulting from the continued evolution to the new value based re-imbursement environment.
"Having enjoyed our positive working relationship for a decade, we now look forward to continuing to deliver sustainable value throughout this new term."
dreamcatcher
- 08 Nov 2017 15:58
- 80 of 99
AGM Statement
RNS
RNS Number : 8493V
Craneware plc
08 November 2017
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
8 November 2017 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 2pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first four months of the year, adding to the recent announcement of the $6m contract win extending the scope of our solutions within an existing customer. In June, we launched Trisus Claims Informatics, the first product on our cloud-based Trisus platform, to which we have seen a positive market response. In addition, we are seeing very encouraging results for the early adopters of our Trisus Cost Analytics Resource Efficiency product, which is currently under development within Craneware Healthcare Intelligence.
"The sales activity and the early product successes demonstrate how we are benefiting from our ongoing investments in our Value Cycle product suite, ensuring we have the solutions that provide insight into key areas of hospital operations, expanding our market opportunity and increasing our strategic value within our market.
"Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.
"This positive impact of the Value Cycle on current sales and underlying pipelines combined with the high levels of revenue visibility and significant cash reserves, means we are well positioned to continue to execute on our growth strategy."
RNS
RNS Number : 8493V
Craneware plc
08 November 2017
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
8 November 2017 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 2pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first four months of the year, adding to the recent announcement of the $6m contract win extending the scope of our solutions within an existing customer. In June, we launched Trisus Claims Informatics, the first product on our cloud-based Trisus platform, to which we have seen a positive market response. In addition, we are seeing very encouraging results for the early adopters of our Trisus Cost Analytics Resource Efficiency product, which is currently under development within Craneware Healthcare Intelligence.
"The sales activity and the early product successes demonstrate how we are benefiting from our ongoing investments in our Value Cycle product suite, ensuring we have the solutions that provide insight into key areas of hospital operations, expanding our market opportunity and increasing our strategic value within our market.
"Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.
"This positive impact of the Value Cycle on current sales and underlying pipelines combined with the high levels of revenue visibility and significant cash reserves, means we are well positioned to continue to execute on our growth strategy."
dreamcatcher
- 10 Nov 2017 16:39
- 81 of 99
Dividend Currency Election
RNS
RNS Number : 2046W
Craneware plc
10 November 2017
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
10 November 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its final dividend announced on 5 September 2017.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.31/£1.
RNS
RNS Number : 2046W
Craneware plc
10 November 2017
Craneware plc
("Craneware" or the "Company")
Dividend Currency Election
10 November 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its final dividend announced on 5 September 2017.
For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.31/£1.
dreamcatcher
- 03 Jan 2018 16:38
- 82 of 99
3 Jan
Peel Hunt
1,800.00
Buy
Peel Hunt
1,800.00
Buy
dreamcatcher
- 08 Jan 2018 07:18
- 83 of 99
Trading Update and Significant Contract Win
RNS
RNS Number : 1640B
Craneware plc
08 January 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Significant Contract Win
8 January 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2017.
The Group is pleased to announce that it has continued to perform strongly in the first half of the financial year as it executes on its growth strategy. There has been strong underlying sales growth which has been extended by a significant new contract with one of the largest healthcare provider networks (the 'Network') in the US, further details provided below.
Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the Group's long term visibility of revenue under contract.
As a result, the Group expects to report increases in both revenue and adjusted EBITDA in the range of 15% to 18% for the six month period ended 31 December 2017, continuing the double digit growth delivered in the prior year.
The Group maintains healthy cash reserves of over $50m (H117: $45m) and has a further funding facility available from the Bank of Scotland of up to $50m. The Group continues to investigate opportunities to deploy these reserves.
With the growth in contracts signed in the period, continued sales momentum and high levels of revenue visibility, the Board is confident in meeting market expectations for the full year.
Significant Contract Win
This contract is expected to deliver in excess of $16m of revenue over its initial five year term as Craneware's Value Cycle solutions are utilised by over 75 new facilities across the Network. Having previously contracted to utilise Craneware's software in a small number of its hospitals, the customer carried out an assessment of the potential financial and operational impact Craneware's solution could bring to the entire Network. This has resulted in the roll out of Craneware's software across the Network with Craneware hosting the solution as part of the Network's strategic financial performance plans.
Notice of Results
The Company will announce results for the six months ended 31 December 2017 on 6 March 2018.
Keith Neilson, CEO of Craneware plc, commented, "These results, including a contract with one of the largest healthcare providers in the US, demonstrate the ongoing momentum we are experiencing in the business.
"The strength of our solutions and the value they deliver to all strata of customers, including large and complex health systems, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers as they look to improve and sustain their financial performance, whilst mitigating operational and compliance risks.
"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its ongoing ability to deliver increasing stakeholder value this year and in the future."
RNS
RNS Number : 1640B
Craneware plc
08 January 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Significant Contract Win
8 January 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2017.
The Group is pleased to announce that it has continued to perform strongly in the first half of the financial year as it executes on its growth strategy. There has been strong underlying sales growth which has been extended by a significant new contract with one of the largest healthcare provider networks (the 'Network') in the US, further details provided below.
Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the Group's long term visibility of revenue under contract.
As a result, the Group expects to report increases in both revenue and adjusted EBITDA in the range of 15% to 18% for the six month period ended 31 December 2017, continuing the double digit growth delivered in the prior year.
The Group maintains healthy cash reserves of over $50m (H117: $45m) and has a further funding facility available from the Bank of Scotland of up to $50m. The Group continues to investigate opportunities to deploy these reserves.
With the growth in contracts signed in the period, continued sales momentum and high levels of revenue visibility, the Board is confident in meeting market expectations for the full year.
Significant Contract Win
This contract is expected to deliver in excess of $16m of revenue over its initial five year term as Craneware's Value Cycle solutions are utilised by over 75 new facilities across the Network. Having previously contracted to utilise Craneware's software in a small number of its hospitals, the customer carried out an assessment of the potential financial and operational impact Craneware's solution could bring to the entire Network. This has resulted in the roll out of Craneware's software across the Network with Craneware hosting the solution as part of the Network's strategic financial performance plans.
Notice of Results
The Company will announce results for the six months ended 31 December 2017 on 6 March 2018.
Keith Neilson, CEO of Craneware plc, commented, "These results, including a contract with one of the largest healthcare providers in the US, demonstrate the ongoing momentum we are experiencing in the business.
"The strength of our solutions and the value they deliver to all strata of customers, including large and complex health systems, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers as they look to improve and sustain their financial performance, whilst mitigating operational and compliance risks.
"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its ongoing ability to deliver increasing stakeholder value this year and in the future."
dreamcatcher
- 16 Jan 2018 19:54
- 84 of 99
dreamcatcher
- 01 Feb 2018 07:22
- 85 of 99
1 Feb
Peel Hunt
1,800.00
Buy
Peel Hunt
1,800.00
Buy
dreamcatcher
- 13 Feb 2018 16:01
- 86 of 99
Significant Contract Wins
RNS
RNS Number : 6550E
Craneware plc
13 February 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Wins
13 February 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce two significant new contracts with hospital providers in the US. Both hospital providers are new customers to Craneware.
The first contract with a large blue chip healthcare provider, sees Craneware's Value Cycle products being deployed across this organisation's 20 hospitals. Craneware's solutions will be an integral part of this provider's major system change, helping to ensure revenue integrity during the initiative and beyond. This contract is expected to deliver c$5m of revenue over its initial multi-year term.
The second contract win with an innovative surgical hospital is for the provision of Craneware's suite of products as part of its strategic growth plans, deploying multiple Craneware solutions, including the Trisus Platform and Trisus Claims Informatics. This provider is focused on improving all aspects of its value cycle. This multi-year contract is expected to deliver c$3.5m of revenue over its initial term.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from these two contracts will be recognised over future periods, adding to the Group's long term visibility of revenue under contract, supporting ongoing financial performance.
Keith Neilson, CEO of Craneware plc, commented, "These contract wins confirm that the positive momentum and financial success we reported in the first half of the year has continued into the second half.
"This is further evidence of the strategic importance and value that Craneware's solutions can bring to all sizes and complexities of hospital healthcare providers, as they look to address the challenges they face with the ongoing evolution of the US Healthcare market.
"This continued momentum across the entire business, combined with the strength of our solution set, means we are well positioned to support our customers in the new era of value-based care and deliver increasing stakeholder value."
RNS
RNS Number : 6550E
Craneware plc
13 February 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Significant Contract Wins
13 February 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce two significant new contracts with hospital providers in the US. Both hospital providers are new customers to Craneware.
The first contract with a large blue chip healthcare provider, sees Craneware's Value Cycle products being deployed across this organisation's 20 hospitals. Craneware's solutions will be an integral part of this provider's major system change, helping to ensure revenue integrity during the initiative and beyond. This contract is expected to deliver c$5m of revenue over its initial multi-year term.
The second contract win with an innovative surgical hospital is for the provision of Craneware's suite of products as part of its strategic growth plans, deploying multiple Craneware solutions, including the Trisus Platform and Trisus Claims Informatics. This provider is focused on improving all aspects of its value cycle. This multi-year contract is expected to deliver c$3.5m of revenue over its initial term.
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from these two contracts will be recognised over future periods, adding to the Group's long term visibility of revenue under contract, supporting ongoing financial performance.
Keith Neilson, CEO of Craneware plc, commented, "These contract wins confirm that the positive momentum and financial success we reported in the first half of the year has continued into the second half.
"This is further evidence of the strategic importance and value that Craneware's solutions can bring to all sizes and complexities of hospital healthcare providers, as they look to address the challenges they face with the ongoing evolution of the US Healthcare market.
"This continued momentum across the entire business, combined with the strength of our solution set, means we are well positioned to support our customers in the new era of value-based care and deliver increasing stakeholder value."
dreamcatcher
- 06 Mar 2018 07:10
- 87 of 99
Half-year Report
RNS
RNS Number : 7619G
Craneware plc
06 March 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Interim Results
6 March 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2017.
Financial Highlights (US dollars)
· Revenue increased 16% to $31.1m (H1 2017: $26.8m)
· Adjusted EBITDA1 increased 18% to $9.7m (H1 2017: $8.2m)
· Profit before tax increased 16% to $8.7m (H1 2017: $7.5m)
· Adjusted basic EPS increased 18% to 25.4 cents per share (H1 2017: 21.6 cents per share)
· Cash position of $52m (H1 2017: $45m) following dividend payment of $4.1m
· Proposed interim dividend increased 15% to 10p (H1 2017: 8.7p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
· Two significant contracts secured in the half, with a further two announced post period end
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with our newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Cost Analytics and Resource Efficiency software (Trisus CARE), the next Trisus software release
Outlook
· Record sales pipeline for the current financial year
· Total visible revenue of over $63.1m for the current financial year and $179.4m for the three-year period to June 2020 (H1 2017 same three year period: $149.1m)
· Board confident in outlook for the year
Keith Neilson, CEO of Craneware plc commented, "Our extensive expertise and experience in the US healthcare market means we are well positioned to provide actionable insight for our customers. By combining their financial and operational data in unique ways, our solutions ensure they can continue to thrive in the new era of value-based care.
"The investments made into Craneware's product suite and operations in recent years means we are now delivering growth rates which are outperforming our industry. We are seeing growing interest across our enlarged product suite and are particularly pleased with the high levels of interest and opportunities across our customer base for our newly launched cloud-based platform, Trisus.
"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the second half of the year with great confidence for the future and the ongoing success of the business."
RNS
RNS Number : 7619G
Craneware plc
06 March 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Interim Results
6 March 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2017.
Financial Highlights (US dollars)
· Revenue increased 16% to $31.1m (H1 2017: $26.8m)
· Adjusted EBITDA1 increased 18% to $9.7m (H1 2017: $8.2m)
· Profit before tax increased 16% to $8.7m (H1 2017: $7.5m)
· Adjusted basic EPS increased 18% to 25.4 cents per share (H1 2017: 21.6 cents per share)
· Cash position of $52m (H1 2017: $45m) following dividend payment of $4.1m
· Proposed interim dividend increased 15% to 10p (H1 2017: 8.7p per share)
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
Operational Highlights
· Two significant contracts secured in the half, with a further two announced post period end
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with our newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Cost Analytics and Resource Efficiency software (Trisus CARE), the next Trisus software release
Outlook
· Record sales pipeline for the current financial year
· Total visible revenue of over $63.1m for the current financial year and $179.4m for the three-year period to June 2020 (H1 2017 same three year period: $149.1m)
· Board confident in outlook for the year
Keith Neilson, CEO of Craneware plc commented, "Our extensive expertise and experience in the US healthcare market means we are well positioned to provide actionable insight for our customers. By combining their financial and operational data in unique ways, our solutions ensure they can continue to thrive in the new era of value-based care.
"The investments made into Craneware's product suite and operations in recent years means we are now delivering growth rates which are outperforming our industry. We are seeing growing interest across our enlarged product suite and are particularly pleased with the high levels of interest and opportunities across our customer base for our newly launched cloud-based platform, Trisus.
"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the second half of the year with great confidence for the future and the ongoing success of the business."
dreamcatcher
- 03 May 2018 17:02
- 88 of 99
08:30 03/05/2018
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and set its price target at 2100p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and set its price target at 2100p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
dreamcatcher
- 10 Jul 2018 07:04
- 89 of 99
Trading Update and Significant Contract Win
RNS
RNS Number : 0806U
Craneware plc
10 July 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Significant Contract Win
10 July 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2018.
The Group is pleased to announce continued outstanding performance, as it executes on its growth strategy. There has been strong underlying new sales growth that increased by approximately 100%. This includes a further significant new contract signed at the end of the year. This contract with a large healthcare provider network ('the Network') in the Eastern US is for the Company's Pharmacy ChargeLink® solution. Further details on the contract are provided below.
Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the acceleration of the Group's long term visibility of revenue under contract.
In addition to this record sales performance, the Group expects to report increases of approximately 16% in revenue and 20% in adjusted EBITDA for the year ended 30 June 2018, extending the run of organic double digit growth delivered in prior years.
Having returned $15m to shareholders and invested a further $4m in the Employee Benefit Trust during the year, the Group's cash conversion has resulted in the cash balances returning to similar levels to those seen at the end of FY17 (FY17: $53m).
Further Significant Contract Win
Craneware has signed a significant new contract, with a large hospital network in the Eastern US, for its Pharmacy ChargeLink® solution. From October 2018, Craneware's solution will be rolled out to the 12 facilities across the Network. This contract is expected to deliver in excess of $6m of revenue over its initial five year term. As per the revenue recognition policy all of the revenue from this contract will be recognised in future periods.
Notice of Results
The Company will announce results for the year ended 30 June 2018 on 4 Sept 2018.
Keith Neilson, CEO of Craneware plc, commented, "These record results demonstrate the ongoing momentum we are seeing across all strata of hospitals including large and complex health systems as they embrace the realities of value-based economics within healthcare.
"The strength of our solutions and the value they deliver to our customers, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers to deliver better healthcare through sustainable financial performance, whilst mitigating operational and compliance risks.
"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its continuing ability to deliver increasing stakeholder value year on year whilst investing in our future."
RNS
RNS Number : 0806U
Craneware plc
10 July 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Trading Update and Significant Contract Win
10 July 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2018.
The Group is pleased to announce continued outstanding performance, as it executes on its growth strategy. There has been strong underlying new sales growth that increased by approximately 100%. This includes a further significant new contract signed at the end of the year. This contract with a large healthcare provider network ('the Network') in the Eastern US is for the Company's Pharmacy ChargeLink® solution. Further details on the contract are provided below.
Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the acceleration of the Group's long term visibility of revenue under contract.
In addition to this record sales performance, the Group expects to report increases of approximately 16% in revenue and 20% in adjusted EBITDA for the year ended 30 June 2018, extending the run of organic double digit growth delivered in prior years.
Having returned $15m to shareholders and invested a further $4m in the Employee Benefit Trust during the year, the Group's cash conversion has resulted in the cash balances returning to similar levels to those seen at the end of FY17 (FY17: $53m).
Further Significant Contract Win
Craneware has signed a significant new contract, with a large hospital network in the Eastern US, for its Pharmacy ChargeLink® solution. From October 2018, Craneware's solution will be rolled out to the 12 facilities across the Network. This contract is expected to deliver in excess of $6m of revenue over its initial five year term. As per the revenue recognition policy all of the revenue from this contract will be recognised in future periods.
Notice of Results
The Company will announce results for the year ended 30 June 2018 on 4 Sept 2018.
Keith Neilson, CEO of Craneware plc, commented, "These record results demonstrate the ongoing momentum we are seeing across all strata of hospitals including large and complex health systems as they embrace the realities of value-based economics within healthcare.
"The strength of our solutions and the value they deliver to our customers, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers to deliver better healthcare through sustainable financial performance, whilst mitigating operational and compliance risks.
"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its continuing ability to deliver increasing stakeholder value year on year whilst investing in our future."
dreamcatcher
- 10 Jul 2018 18:12
- 90 of 99
09:20 10/07/2018
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2500p (from 2100p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2500p (from 2100p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
dreamcatcher
- 04 Sep 2018 07:05
- 91 of 99
Final Results
RNS
RNS Number : 6425Z
Craneware plc
04 September 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
4 September 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its audited results for the year ended 30 June 2018.
Financial Highlights (US dollars)
· Revenue increased 16% to $67.1m (FY17: $57.8m)
· Adjusted EBITDA1. increased 20% to $21.6m (FY17: $18.0m)
· Profit before tax increased 12% to $18.9m (FY17: $16.9m)
· Basic adjusted EPS2. increased 17% to $0.602 (FY17: $0.514) and adjusted diluted EPS increased to $0.591 (FY17: $0.503)
· Total visible revenue increased 20% to $192.9m (FY17 same 3 year period: $160.7m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Renewal rate remains above 100% by dollar value
· Cash at year-end of $52.8m (FY17: $53.2m) after having returned $23.2m to shareholders via a share buyback and dividends, while also investing $4.2m in the Employee Benefit Trust
· Proposed final dividend of 14.0p (18.48 cents) (FY17: 11.3p, 14.71 cents) per share giving a total dividend for the year of 24.0p (36.68 cents) (FY17: 20.0p, 26.04 cents) per share
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments.
2. Adjusted Earnings per share calculations allow for the tax adjusted acquisition costs and share related transactions together with amortisation on acquired intangible assets.
Operational Highlights
· Over 100% increase in new sales in the year, including five significant contracts wins or contract extensions
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Craneware Healthcare Intelligence software, the next Trisus software release
Outlook
· Record sales pipeline for the current financial year
· Board confident in outlook for the year and beyond
Keith Neilson, CEO of Craneware plc commented, "While the past year has been outstanding in terms of financial results and operational progress, this is by no means the end of the journey and we are excited by the far greater opportunity that lies ahead. It is clear that the investments we have made into the organisation's design, people and products are delivering excellent results, and we will continue to invest in our people and business to ensure we have the capabilities to succeed. We believe that the breadth of our customer base and the quantity of data within our solutions means we have the opportunity to sit at the heart of the move to value-based economics; collating and analysing the information that will support hospital-wide decision making and ultimately have a positive impact on the quality of healthcare.
"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the new financial year with great confidence for the future and the ongoing success of the business."
RNS
RNS Number : 6425Z
Craneware plc
04 September 2018
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
4 September 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its audited results for the year ended 30 June 2018.
Financial Highlights (US dollars)
· Revenue increased 16% to $67.1m (FY17: $57.8m)
· Adjusted EBITDA1. increased 20% to $21.6m (FY17: $18.0m)
· Profit before tax increased 12% to $18.9m (FY17: $16.9m)
· Basic adjusted EPS2. increased 17% to $0.602 (FY17: $0.514) and adjusted diluted EPS increased to $0.591 (FY17: $0.503)
· Total visible revenue increased 20% to $192.9m (FY17 same 3 year period: $160.7m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Renewal rate remains above 100% by dollar value
· Cash at year-end of $52.8m (FY17: $53.2m) after having returned $23.2m to shareholders via a share buyback and dividends, while also investing $4.2m in the Employee Benefit Trust
· Proposed final dividend of 14.0p (18.48 cents) (FY17: 11.3p, 14.71 cents) per share giving a total dividend for the year of 24.0p (36.68 cents) (FY17: 20.0p, 26.04 cents) per share
1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments.
2. Adjusted Earnings per share calculations allow for the tax adjusted acquisition costs and share related transactions together with amortisation on acquired intangible assets.
Operational Highlights
· Over 100% increase in new sales in the year, including five significant contracts wins or contract extensions
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Craneware Healthcare Intelligence software, the next Trisus software release
Outlook
· Record sales pipeline for the current financial year
· Board confident in outlook for the year and beyond
Keith Neilson, CEO of Craneware plc commented, "While the past year has been outstanding in terms of financial results and operational progress, this is by no means the end of the journey and we are excited by the far greater opportunity that lies ahead. It is clear that the investments we have made into the organisation's design, people and products are delivering excellent results, and we will continue to invest in our people and business to ensure we have the capabilities to succeed. We believe that the breadth of our customer base and the quantity of data within our solutions means we have the opportunity to sit at the heart of the move to value-based economics; collating and analysing the information that will support hospital-wide decision making and ultimately have a positive impact on the quality of healthcare.
"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the new financial year with great confidence for the future and the ongoing success of the business."
dreamcatcher
- 04 Sep 2018 17:34
- 92 of 99
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2800p (from 2500p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2800p (from 2500p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
dreamcatcher
- 05 Sep 2018 16:27
- 93 of 99
dreamcatcher
- 10 Sep 2018 13:42
- 94 of 99
Director Deals - Craneware PLC (CRW)
BFN
Keith Neilson, Chief Executive Officer, bought 4,848 shares in the company on the 7th September 2018 at a price of 3081.91p. The Director now holds 3,382,647 shares.
Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk
BFN
Keith Neilson, Chief Executive Officer, bought 4,848 shares in the company on the 7th September 2018 at a price of 3081.91p. The Director now holds 3,382,647 shares.
Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk
dreamcatcher
- 13 Sep 2018 16:53
- 95 of 99
500p above latest broker price and new high.
dreamcatcher
- 14 Sep 2018 15:58
- 96 of 99
Going into orbit.
dreamcatcher
- 06 Nov 2018 07:08
- 97 of 99
AGM Statement and Capital Markets Day
RNS
RNS Number : 3859G
Craneware plc
06 November 2018
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement and Capital Markets Day
6 November 2018 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 1pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first four months of the year, in line with management expectations. Strong demand has continued across our enlarged product suite, from both new and existing customers.
"Our recent Financial Performance Summit in the US was the most well attended in the history of the Company, with representatives from approximately 600 hospitals. From the workshops and panel discussions at the event, it is evident that the move to value-based care is growing in momentum and hospitals are preparing for this shift. As we launch our new Trisus products over the coming weeks and continue to invest in future products over the coming years, we see the opportunity for Craneware to become a major player in the healthcare market, ensuring hospitals have the tools to thrive in this near era, improving both margins and patient outcomes.
"With a continued high level of recurring revenues, a growing customer base, healthy cash balances and significantly increased addressable market through our expanding product suite, we look to the future with confidence."
Capital Markets Day
Craneware is holding a Capital Markets Day for institutional investors and analysts this morning at 9am in the offices of Peel Hunt in London. The presentations will discuss the evolution of the US healthcare market and provide further insight into Craneware's newly launched Trisus products, including Trisus Healthcare Intelligence. Keith Neilson, CEO, and Craig Preston, CFO, will be joined by other members of the Craneware Board and senior leadership team. No further update on trading will be provided.
RNS
RNS Number : 3859G
Craneware plc
06 November 2018
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement and Capital Markets Day
6 November 2018 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 1pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
"We have experienced a positive start to trading in the first four months of the year, in line with management expectations. Strong demand has continued across our enlarged product suite, from both new and existing customers.
"Our recent Financial Performance Summit in the US was the most well attended in the history of the Company, with representatives from approximately 600 hospitals. From the workshops and panel discussions at the event, it is evident that the move to value-based care is growing in momentum and hospitals are preparing for this shift. As we launch our new Trisus products over the coming weeks and continue to invest in future products over the coming years, we see the opportunity for Craneware to become a major player in the healthcare market, ensuring hospitals have the tools to thrive in this near era, improving both margins and patient outcomes.
"With a continued high level of recurring revenues, a growing customer base, healthy cash balances and significantly increased addressable market through our expanding product suite, we look to the future with confidence."
Capital Markets Day
Craneware is holding a Capital Markets Day for institutional investors and analysts this morning at 9am in the offices of Peel Hunt in London. The presentations will discuss the evolution of the US healthcare market and provide further insight into Craneware's newly launched Trisus products, including Trisus Healthcare Intelligence. Keith Neilson, CEO, and Craig Preston, CFO, will be joined by other members of the Craneware Board and senior leadership team. No further update on trading will be provided.
dreamcatcher
- 15 Nov 2018 16:16
- 98 of 99
10:30 15/11/2018
Broker Forecast - Berenberg issues a broker note on Craneware PLC
Berenberg today initiates coverage of Craneware PLC (LON:CRW) with a buy investment rating and price target of 3600p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
Broker Forecast - Berenberg issues a broker note on Craneware PLC
Berenberg today initiates coverage of Craneware PLC (LON:CRW) with a buy investment rating and price target of 3600p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
cynic
- 15 Nov 2018 16:38
- 99 of 99
i really cannot get excited about this stock though many do ....... it's totally illiquid and MM-only with a spread that is usually 100/200p
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter